SlideShare a Scribd company logo
1 of 24
Download to read offline
Pediatric Guidelines for IV Medication Administration
NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist.
Version 9/28/2008 Barb Maas Pharm. D.
1
Approved For
Drug
ICU
ED
Telemetry
Required
Acute
Care
IVP
IV
Infusion
Concent-
ration
Usual Dosing and
Administration
Comments
Acetazolamide
(Diamox®
)
X X X Dilute to
MAX of
100 mg/mL
5-10 mg/kg/dose MR q 8 or 6 hrs.
MAX dose: 25 mg/kg/dose up to 500 mg/dose
MAX Rate: IVP over 1 minute.
Monitor serum electrolytes
Acetylcysteine
(Acetadote®)
X
Bolus
+
infusion
X
Infusion
only
X 30 gm/1000
mL
(30 mg/mL)
Requires toxicology approval.
Bolus: 150mg/kg over 1 hr.
Maintenance: 15-7.5mg/kg/hr. See dosing protocol or
contact pharmacy for weight-based protocol.
When used in acetaminophen overdose,
monitor serum acetaminophen concentrations;
monitor LFTs. Bolus doses, monitor for
hypotension, flushing, anaphylaxis
Bolus doses must be completed in critical care
areas only. Maintenance IV infusions may be
continued or initiated in acute care areas.
Acyclovir X X X Diluted to
<5 mg/mL
Infusion over 60-90 minutes. Dose: 5-20 mg/kg/dose q
8hrs.
Patient should be well hydrated to prevent
nephrotoxicity. Monitor urine output, Scr.
Adenosine
(Adenocard®
)
X X X
See
restriction
.
X 6 mg/2 mL.
(3mg/ml)
DOSE:0.05-0.1 mg/kg up to 6 mg over 1-2 seconds
followed by rapid NS flush. May increase dose by 0.1-
0.2 mg/kg q2 minutes up to 12 mg/dose every 1-2 mins
till termination of arrhythmia to a MAX CUM dose of
0.3 mg/kg/dose upto 30 mg.
> 50kg: 6mg, 12mg, 12mg
Restriction: In acute care areas, doses must
be administered by a physician. .
Communication with the ICU team prior to
adenosine administration is required. An
attending Hospitalist, Cardiologist, or ICU
physician must be at the bedside.
A continuous ECG rhythm strip must be
obtained during dosing to monitor and
document drug effects
Albumin 5%
(forhypovolemia,
hypoalbuminemia
X X X 5%
(50 mg/mL)
0.5-1 gm/kg/dose (10-20 mLs/kg/dose). Infusion over 30-
60 minutes. In emergencies, may administer over 15
minutes.
Adult MAX: 600mls/hr
Rapid infusion may cause hypertension and
pulmonary edema. Monitor vital signs and
fluid balance. Use within 4 hours of opening
vial.
60 micron filter/tubing supplied by pharmacy
Albumin 25%
(forhypoproteinemia
w/ generalized edema)
X X X 25%
(250 mg/mL)
0.25-1 gm/kg/dose (1-4 ms/kg/dose)
Infusion as tolerated over 30-120 minutes.
Adult MAX :180ml/hr
Rapid infusion may cause hypertension &
pulmonary edema. Monitor vital signs and
fluid balance. Use within 4 hrs of opening.
60 micron filter/tubing supplied by pharmacy
Alprostadil, PGE1
Prostin VR
Pediatric®)
X X X
Contin-
uous
infusion
Dilute 500
mcg in
50mls NS
(10 mcg/ml)
Initial: 0.05- 0.1 mcg/kg/min.
Range: 0.01 up to MAX 0.4mcg/kg/minute
Infuse via large vein.
Monitor arterial pressure, RR, HR, oxygen
saturation, temp.
Amikacin
(Amikin®)
X X X Diluted to
< 5 mg/mL
5-10mg/kg/dose q8hrs with NL renal function.
Infusion: Over 30 minutes.
Urine output, Serum creatinine,
Peak and trough concentrations.
Pediatric Guidelines for IV Medication Administration
NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist.
Version 9/28/2008 Barb Maas Pharm. D.
2
Approved For
DrugDrD
ICU
ED
Telemetry
Required
Acute
Care
IVP
IV
Infusion
Concen-
tration
Usual Dosing and
Administration
Comments
Amiodarone
(Cordarone®)
X X X
Bolus in
code only
No
infusion
X X Bolus diluted to
1.5-3 mg/mLin
D5W
Infusion 450
mg/ 250 mL in
D5W
BOLUS: PALS for pulseless VF/VT5 mg/kg (MAX
300 mg/dose) given over 5-10 minutes. - 0.22 micron
filter preferred . Flush post dose.
For perfusing VF/VT 5 mg/kg over 20-60 min, MR X
3
Infusion: Initial dose of 5 mcg/kg/min, increase to
desired effect to a MAX of 15 mcg/kg/min
Central line preferred for concentrations
exceeding 2 mg/mL. Dedicated filtered
(0.22 micron) line required.
Continuous BP/cardiac monitoring, thyroid
function, LFTs, and pulmonary function
should be monitored frequently.
Ampicillin X X X
slow
X Dilute to <20
mg/mL
IVP: not to exceed 10 mg/kg/minute.
Infusion: over 15-30 minutes
Dosing: 100-400 mg/kg/day divided every 6 hrs.
MAX 12 gm/day
Adjust with renal dysfunction.
Ampicillin/
Sulbactam
(Unasyn®)
X X X
slow
X Dilute to
<30 mg/mL
=(amp 20 mg/
sulb 10 mg)
IVP: not to exceed 15 mg/kg/minute (amp/sulb)
Infusion: Over 15-30 minutes
>1 month: 150-225 mg/kg/day (amp/sulb) divided
every 6 hrs
Children: 150-300 mg/kg/day (amp/sulb) divided
every 6 hrs. (non-meningitic doses)
(MAX dose: 12 gm ampisulb/day)
Unsayn: Each 1.5mg unasyn=1mg apicillin
+0.5mg sulbactam.
With prolonged therapy, monitor
hematologic, renal and hepatic function.
Observe for change in bowel frequency.
Atropine X X X
MD
available
X 0.1 mg/mL;
1 mg/mL
IV Push: given over 1 minute
Dosing: 0.01-0.2 mg/kg (MIN 0.1 mg)
Child: up to 0.5 mg, MRx1
Adolescent: up to 1 mg, MRx 1
Please see reference for dosing for specific
indications.
Monitor vital signs and EKG; monitor for
side effects including dry mouth, dizziness
and palpitations.
Azithromycin
(Zithromax®)
X X X Dilute to 2
mg/mL
Infusion:MAX concentration of 2 mg/mL
over 1 hr
Dosing: 5-10 mg/kg/day as q 24 h
(MAX 500 mg)
Single dose regimen: 30mg/kg X 1 (MAX 1500mg)
For specific indications, please consult
pedi reference for recommendations.
Monitor for pain at infusion site, LFTs,
WBC and infection.
Aztreonam
(Azactam®)
X X X X Dilute to
< 20 mg/mL
IVP: over 3-5 min
Infusion: Over 20 minutes
Dosing: >1 month-90-120 mg/kg/day div q 8h or q 6
h. CF: 50 mg/kg/dose q 6 hrs MAX 8 gm/day
Adjust dosing with renal dysfunction.
Pediatric Guidelines for IV Medication Administration
NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist.
Version 9/28/2008 Barb Maas Pharm. D.
3
Approved For
Drug
ICU
ED
Telemetry
Required
Acute
Care
IVP
IV
Infusion
Concen-
tration
Usual Dosing and
Administration
Comments
Bumetanide
(Bumex®)
X X X X 0.25 mg/mL Dosing:0.015-0.1 mg/kg/dose up to 4 mg q 6-24 hrs (MAX
dose is 10 mg/day, 20 mg/day w/ RF))
IV Push: over 1-2 minutes MAX 1mg/min
Monitor blood pressure, serum
electrolytes and renal function.
Caffeine Citrate
(Cafcit)
For apnea
X X X 20 mg/mL
citrate salt
(=10 mg/mL
caffeine base)
Loading: 10-20 mg/kg citrate salt infused over
30 minutes
Maintenance: 5 mg/kg/day as citrate salt once daily starting
24 hours after bolus doseinfused over ≥ 10 minutes
Clarify if dosing is as citrate salt or
caffeine base. Must be specified on
medication order.
May dilute in D5W
Monitor heart rate, number and
severity of apnea spells, and serum
caffeine levels
Caffeine sodium
benzoate
For spinal
headache
X X X Dilute to 0.5
mg/mL
Adults: 500 mgs as a single dosediluted with 1000 mL NS
and infused over 1 hour, followed by 1000 mL NS over 1
hour.
Not to be administered in
neonates(benzoates). Monitor heart
rate.
Calcium Chloride X
Slow IVP
X IVP In
code only
w/MD
present.
No
infusion.
X
Slow
IVP
X 1 gm/
10 mL vial
Recommend use only in symptomatic hypocalcemia
Bolus: 10-20 mg/kg/dose up to 1gm over a minimum of 10
minutes.
Infusion: Do not exceed 45-90 mg/kg given over 1 hour
Central Line preferred unless
emergency administration.
Do not administer I.M. or S.C. or use
scalp, small hand or foot veins for IV
administration since severe necrosis
may occur. Monitor serum calcium
(ionized calcium is recommended),
heart rate and EKG. Do not infuse
calcium chloride in same IV line as
phosphate-containing solutions.
Calcium Gluconate X
Slow IVP
X
Slow IVP
only.
Slow IVP
in code
w/ MD
present.
Infusion
OK
X
Slow
IVP
X 1 gm/50 mL
=20 mg/mL
200-500 mg/kg/DAY as continuous infusion or in 4 divided
doses
Acute::Usual 100mg/kg or 1gm MAX 3gm over 10 minutes
Non-Acute: Usual 50-100mg/kg not to exceed 2gm over no
less than 60 minutes.
MAX: 200mg/kg up to 3gm
Do not infuse calcium gluconate in
same IV line as phosphate-containing
solutions.
Monitor serum calcium (ionized
calcium is recommended), heart rate
and EKG.
See label comments on Pedi IV
Calcium Gluconate Bags
Cefazolin (Kefzol) X X X X Dilute to
< 20mg/ml
IVP: Over 3-5 minutes
Infusion: Over 10-15 minutes
Dosing:Neonates>2 kg, + 7 days-60 mg/kg/day div q 8h.
Infants/Children: 50-100 mg/kg/day div q 8h
Adolescent/Adult: 1-2 gm IV q 8h
MAX ADULT DOSE: 12 gm/day
Adjust dosing with renal dysfunction.
Pediatric Guidelines for IV Medication Administration
NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist.
Version 9/28/2008 Barb Maas Pharm. D.
4
Approved For
Drug
ICU
ED
Telemetry
Required
Acute
Care
IVP
IV
Infusion
Concen-
tration
Usual Dosing and
Administration
Comments
Cefepime
(Maxipime)
X X X X Dilute to
< 20 mg/mL
IVP over 5 minutes.
Infusion over 30 minutes
Dosing 2 mo-16yo: 100-150 mg/kg/day div q 12 or 8 hrs.
CF 50 mg/kg/dose q 8hr MAX 6 gm/day
ID approval required for patients
outside the ICU. Pseudomonal
infections should be dosed at the
higher end of the dosing range.
Adjust dosing with renal dysfunction.
Cefotaxime
(Claforan®)
X X X X Dilute to
< 40 mg/mL
IVP over 3-5 minutes
Infusion: Over 10-30 minutes
<7 days:+>2000 g:100-150 mg/kg/day div every 8-12 hrs
> 7 days: >2000 g: 150-200 mg/kg/day divided every 6-8
hrs
1 month- 12 years: <50 kg: 100-200 mg/kg/day divided
every 6-8 hoursMeningitis: 200-300 mg/kg/day divided
every 4 or 6 hours (MAX 12 gm/day)
> 50 kg: Moderate infection 1-2 gms q 6-8hrs, Severe 2 gms
every 4 to6 hrs (MAX 12 g/day)
Indicated in neonate < 2 weeks or in
infants with clinically relevant
hyperbilirubinemia who may be at
risk for kernicturus.
With prolonged therapy, monitor
renal, hepatic, and hematologic
function periodically; number and
type of stools/day for diarrhea.
Adjust dosing with renal dysfunction.
Cefoxitin
(Mefoxin®)
X X X X Dilute to
< 40mg/ml
IVP over 5 minutes
Infusion over 10-30 minutes
Adjust dosing with renal dysfunction.
Monitor INR with prolonged use
Ceftazidime
(Fortaz)
X X X X Dilute to
<40 mg/mL
IVP over 3-5 minutes
Infusion over 20-60 minutes
< 7days >2 kg: 100-150 mg/kg/day div q 8-12 hrs
>7 days >2 kg: 150 mg/kg/day div q 8h
Infant/child: 100-150 mg/kg/day div q 8h
CF: 150-300 mg/kg/day usual MAX 12 gm/day
CO2 is produced with reconstitution.
Remove pressure/air by venting vial
prior to drawing up dose—
Adjust dosing with renal
dysfunction..
Ceftriaxone
(Rocephin®)
X X X X Dilute to
< 20 mg/mL
IVP over 5 minutes
Infusion over 10-30 minutes
Infants and Children: 50-75 mg/kg/day divided every 12-
24 hours
Meningitis: 80-100 mg/kg/day divided every 12-24 hrs
(MAX: 4 gm/day)
*Do not use in any child <5kg,
unless short-term IV access is
unavailable. Avoid concurrent use in
all patients requiring IV calcium
supplementation.
Monitor CBC, platelet count, renal
and hepatic function tests
periodically, number and type of
stools/day for diarrhea.
Chlorothiazide
(Diuril®)
X X X X 500 mg vial
diluted with 18
mL SWI for a
final
concentration
of 27.8 mg/mL
IVPover 3-5
Infusionover 30 minutes in dextrose or NS
<6 months: 2-8 mg/kg/day in 2 divided doses up to 20
mg/kg/day
>6 months: 4 mg/kg/day in 1-2 divided doses up to 20
mg/kg/day.
Do not administer I.M. or S.C. since
extremely irritating to tissues. May
be further diluted. Monitor serum
electrolytes and blood pressure.
Pediatric Guidelines for IV Medication Administration
NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist.
Version 9/28/2008 Barb Maas Pharm. D.
5
Approved For
Drug
ICU
ED
Telemetry
Required
Acute
Care
IVP
IV
Infusion
Concen-
tration
Usual Dosing and
Administration
Comments
Ciprofloxacin
(Cipro®)
X X X Dilute to
< 2 mg/mL
Infusion over 60 minutes
Children 20-30 mg/kg/day divided q 12 h
CF: 30 mg/kg/day divided q 8 or 12 hrs
May cause venous irritation
Cisatricurium
(Nimbex®)
HIGH RISK MED
X X X 40 mg/100 mL
200mg/500ml
MAX: 200
mg/100 mL
Bolus:IVP: 0.1-0.2mg/kg over 5-10 seconds
Infusion: 1-4 mcg/kg/minMAX 10 mcg/kg/min
Monitor muscle twitch response to
peripheral nerve stimulation, heart
rate and blood pressure
Not renally orhepatically
metabolized
Clindamycin
(Cleocin®)
X X X Dilute to
< 18 mg/mL
Infusion over 10-30 minutes, not to exceed 0.5
mg/kg/minute
Dose: 20-40 mg/kg/day divided q 6 or 8 hrs
Usual adult 600-900 mg IV q 8h
MAX 4.8 gm/day
Cyclosporine
(Sandimmune®)
X X X Dilute in D5W
to
< 2.5 mg/mL
Initial: 5-6 mg/kg/dose (1/3 of oral dose) administered 4-12
hours prior to transplant
Maintenance: 2-10 mg/kg/day in 2 divided doses.
May be administered over 2-6 hours or as a continuous
infusion.
Doses prepared in glass. Use Non
PVC tubing( ie// nitro tubing)
Patients should be monitored
continuously for ≥ the first 30
minutes of the infusion for signs of
anaphylaxis. Monitor serum drug
levels, serum creatinine and BP
D10W X X X X 100 mg/mL Neonates: 100-200 mg/kg /dose (=1-2 mLs/kg) over 1
minute.
Monitor blood and urine sugar, serum
electrolytes and I & O.
D25W X X X X 250 mg/ML
2.5GM/10ML
SYRINGE
Bolus: MAX of 200 mg/kg (=0.8 mLs/kg) over 1 minute not
to exceed 6 mLs/minute if undiluted
Infants <6 month: 0.25-0.5 gm/kg/dose (=1-2 mLs/kg)
MAX of 25 g(50 mLs/dose)
Infants >6 months-40 kg: 0.5-1 g/kg/dose (=2-4 mLs/kg);
MAX of 25 g(50 mLs)/dose
Hyperkalemia<40kg D25W-2mls/kg(0.5gm/kg) over
15-30 minutes + insulin regular 0.1unit/kg IV (MAX 50ml
(=25gm) +5 units insulin/dose.
For peripheral venous administration,
dilute dextrose to MAX
concentration of 12.5%. (1:1 with
NS)preferred. Monitor blood and
urine sugar, serum electrolytes and I
& O.
D50W X X X 500 mg/mL
25gm/50ml
syringe
Bolus: >40 kg not to exceed 3 mls/minute if undiluted
Adolscent/Adult: 25-50 gms (50-100 mLs) over 5-30
minutes
Hyperkalemia:adolescent/adult 25-50 gm + 5-10 units
insulin (5gm (10ml) per 1 unit insulin) over 5-60 minutes.
Avoid in infants/ young children.
Dextrose 10-25% preferred.
Peripheral: Dilution to 12.5% (1:3
D50:NS) preferred.
Pediatric Guidelines for IV Medication Administration
NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist.
Version 9/28/2008 Barb Maas Pharm. D.
6
Approved For
Drug
ICU
ED
Telemetry
Required
Acute
Care
IV
P
IV
Infusion
Concen-
ration Usual Dosing and
Administration
Comments
Dexamethasone
(Decadron)
X X X 4 mg/mL Please see reference for dosing for specific indications
(usual range 0.3-2 mg/kg/day as a generally up to 40
mg/day) divided q 6-24 hrs.
If dose <10 mg, administer IV push over 1-4 minutes.
If dose >10 mg, dilute with D5W or NS and infuse over 15-
30 mins
Monitor hemoglobin, occult blood
loss, serum potassium and glucose.
Dexmedetomidine
(Precedex)
X X X
Moderate
sedation
service
+
moderate
sedation
RN
X 200 mcg/50 mL
(4mcg/ml)
Requires pediatric ICU, moderate sedation service, or
anesthesiology attending approval
Bolus( attending present) 0.5-1 mcg/kg over 10 minutes
Infusion: Usual 0.2-0.7 mcg/kg/hr. Higher doses have
been used.
Ensure airway and respiratory support
measures in place, monitor level of
sedation, heart rate, respiration,
rhythm.
Bolus doses associated with
bradycardia and hypotension.
Diazepam (Valium) X X X X 5 mg/mL IVP: Peds< 40 kg not to exceed 1-2 mg/min, >40 kg 5
mg/min
Dose:0.04-0.3 mg/kg/dose (up to 10 mg/dose) every 2-4
hours to MAX of 0.6 mg/kg within an 8-hour period if
needed.
May cause phlebitis
Monitor heart rate, respiratory rate,
blood pressure and mental status
Digoxin (Lanoxin) X MD adminis-
tration for
loading doses
only.
X
Maint-
enance
doses
X Dilute to < 100
mcg/mL w/NS
Infusion:Slowly administer over 5-10 mins
Dosing: See age specific references
Loading Dose: range 10-30 mg/kg divided in 3 doses over
16-24 hrs (as 50%/25%/25%) not to exceed total 1 mg dose.
Maintenance: approx 1/3 of loading dose divided q 12 or
24 hrs. Rarely exceeds 10 mcg/kg/day up to 0.25 mg/day.
c
Loading dose requires telemetry. Not
for maintenance dose. Monitor heart
rate, rhythm, periodic EKGs, serum
electrolytes, renal function and serum
levels.
Digoxin Immune
Fab
(DigiFAB)
X X X X Dilute to 1-10
mg/mL with NS
Requires toxicology consult! Dosing based on amount of
digoxin ingested. Each 40mg vial binds 0.5mg digoxin
IVP: If in Cardiac Arrest over3-5 minutes using. Infusion
preferred.
Infusion:Over 15-30 minutes through 0.22 micron filter.
Decrease rate or hold if infusion reaction occurs.
0.22 micron filter required
Monitor EKG, serum potassium and
digoxin serum levels.
Check for S/S of an acute allergic
reaction.
Diltiazem
(Cardizem)
X X X X 5 mg/mL for IVP
Infusion 1
mg/mL
Bolus: 0.25 mg/kg over 2- 5 minutes; if inadequate
response, 0.35 mg/kg dose may be administered after 15
minutes
Infusioncontinuous(start after IV bolus doses)
< 50 kg (limited data) 0.05-0.15 mg/kg/hr up to 15 mg/hr
Adult: 5-15 mg/hr
During administration monitor EKG,
heart rate, blood pressure and renal
function.
Diphenhydramine
(Benadryl)
X X X Dilute to <50
mg/mL
IVP:0.5 mg/kg/min up to 25 mg/minute
Infusion: Over 10-15 minutes
Dosing: 0.5-2 mkg/dose(MAX 100 mg) up to 5
mg/kg/day(MAX 300 mg) divided q 6 hrs
Monitor symptom relief and sedation
Pediatric Guidelines for IV Medication Administration
NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist.
Version 9/28/2008 Barb Maas Pharm. D.
7
Approved For
Drug
ICU
ED
Telemetry
Required
Acute
Care
IV
P
IV
Infusion
Concen-
tration Usual Dosing and
Administration
Comments
Dobutamine X X X <10 kg 250 mg
/250 mls
> 10kg500 mg
/250 mls
MAX: 1000
mg/250 mL
Infusion: continuous at 2-20 mcg/kg/minute.
MAX 30 mcg/kg/min
Monitor EKG, blood pressure, heart rate,
CVP, MAP and urine output.
Dopamine X X X <10 kg 200 mg
/250 mL
>10kg 400 mg
/250 mL
MAX: 800 mg/
250 mL
Infusion: continuous at 1-20 mcg/kg/min; titrate to
desired response; MAX dose 30 mcg/kg/min. Central
line preferred.
Monitor EKG, blood pressure, heart rate,
CVP, MAP and urine output.
Doxycycline
(Vibramycin)
X X X Dilute to <=1
mg/mL
Infusion: Doses < 100 mg over 1-2 hrs
Children: (rarely used) 2-5 mg/kg/day divided q 12 or
q 24 hrs not to exceed 100 mg/dose
Adolescents/Adults:Rarely exceeds 200 mg/day.
May cause phlebitis, dizziness, N/V
Droperidol
(Inapsine)
X X
In pts w/
cardiac history
X X 2.5 mg/mL
MAX: 2.5
mg/mL
IVP: Slowly over 2-5 minutes
Postop nausea/vomiting prophylaxis 0.05-0.06
mg/kg/dose; MAX 0.1 mg/kg up to 2.5 mg
Postop nausea/vomiting treatment: 0.01-0.03
mg/kg/dose; MAX 0.1 mg/kg up to 2.5 mg
Adult: 0.625-2.5 mg/dose
Monitor blood pressure, heart rate,
respiratory rate, temperature, serum
potassium and magnesium. Observe for
dystonias and extrapyramadial side effects.
EKG monitoring is recommended in
patients with a history of QT prolongation
or cardiac disease.
Enalaprilat
(Vasotec)
X X X
MD
available
X < 1.25 mg/mL I5-10 mcg/kg/dose administered every 8-24 hours (as
determined by blood pressure readings) over 5-15
minutes.
MAX: 60 mcg/kg/day, rarely to exceed 20 mg/day
Clinical response seen within 15 minutes,
peak within 4 hrs. Monitor blood pressure,
renal function, WBC, serum potassium and
serum glucose.
Enoxaparin
(Lovenox)
X X S
C
SC 100 mg/mL
For doses <10
mg, a special
dilution
of 20mg/ml will
be prepared by
pharmacy
Infants <2 months:
Prophylaxis: 0.75 mg/kg every 12 hrs
Treatment: 1.5 mg/kg every 12 hours
Infants >2 months and <18 years:
Prophylaxis: 0.5 mg/kg every 12 hours
Treatment: 1 mg/kg every 12 hours
Deep SC administration preferred(not im)
and allowed in all nursing units. Do not rub
injection site after administration. Monitor
CBC, platelets, stool occult blood tests. If
antifactorXa level are indicated, draw peak
levels 4 hrs post dose.
Pediatric Guidelines for IV Medication Administration
NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist.
Version 9/28/2008 Barb Maas Pharm. D.
8
Approved For
Drug
ICU
ED
Telemetry
Required
Acute
Care
IV
P
IV
Infusion
Concen
tration Usual Dosing and
Administration
Comments
Epinephrine
(Adrenalin®
)
X X X
SC, IVP
For
anaphy-
laxis,
CPR
X X For IVP 1:10,000 
(0.1 mg/mL)
For ET/ SC /Drips
1:1,000 (1 mg/mL)
Drip Concentrations
< 10 kg 8mg /
250mls
10-50kg 16 mg/
250mls
>50 kg 4 mg/
250 mls
MAX:
16 mg/250 mL-
IV Push: 0.01 mg/kg (=0.1 mL/kg) up to 1 mg (10
mLs) over 1 minute, every 3-5 minsprn.
Infusion: 0.1-1 mcg/kg/min; titrate dose to desired
effect. Central line preferred.
Do not use if pink in color. Monitor EKG,
heart rate, blood pressure, pulmonary
function and injection site monitoring for
extravasation.
Ertapenem (Invanz®
) X X X Dilute to < 20
mg/mL in NS only.
Infusion: Over 30 minutes.
3 mths-12yrs: 15 mg/kg/dose q 12 h up to
1 gm/24 hrs
Adolescent/Adult: 1 gm q 24 hrs.
Do not infuse with dextrose containing
solutions.
Erythropoetin
(EPO®
, Procrit®
)
X X X Various, may be
given undiluted or
diluted 1:1 with NS
IVPush:Over no less than 1 minute, SC
preferred,
See pediatric dosing recommendations for disease
specific guidelines. Range 10-600units/kg
Do not shake vial. Monitor Hgb/Hct, Iron
stores, BP
Esmolol (Brevibloc®
) X X X X <10 mg/mLfor
IVP
20 mg/mL drip
Bolus: 250-500 mcg/kg over 1-2 minutes
Infusion: 50-300 mcg/kg/min; titrate up every 20
mins to desired effect. Dosing may be higher with
SVT (up to 1000 mcg/kg/min in small children)
EKG, BP, HR, respiratory rate monitoring
mandatory during administration.
Esomeprazole
(Nexium®
)
X X X X < 4mg/ml 1-2 mg/kg/day administered in 1-2 divided doses.
Usual adult dose 20-40 mg/day MAX 80 mg
IVP: Dilute with 5 mLs NS per vial and push over
≥ 3 minutes.
Infusion: Add 40mg to 100ml
Gastric pH monitoring may be needed in
select patients.
Etomidate X X
Per moderate
sedation
protocol
X
Moderate
sedation
service
+ sedation
RN
X 2mg/ml
20 and 40mg
vials
Moderate Sedation for Short Procedures: -.1-
0.2mg/kg/dose
RSI/ induction of Anesthesia: 0.3mg/kg IV (-.2-
0.6mg/kg)
IVP: Over 30-60 seconds
Has no analgesic properties.
Requires moderate sedation monitoring
with procedure related use.
May result in transient myoclonus. Avoid
small vessels on the dorsum of the head or
hand. May cause discomfort at injection
site.
Pediatric Guidelines for IV Medication Administration
NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist.
Version 9/28/2008 Barb Maas Pharm. D.
9
Approved For
Drug
ICU
ED
Telemetry
Required
Acute
Care
IV
P
IV
Infusion
Concen
tration Usual Dosing and
Administration
Comments
Famotidine
(Pepcid®)
X X X Dilute to
>=4mg/ml
<3 months: 0.5 mg/kg/dose once daily
3 mths-1 yr: 0.5 mg/kg/dose twice daily
1-12 yrs: 0.5-1 mg/kg/day divided twice daily
IVP: Over > 2 minutes. MAX 10 mg/min
Infusion: Over 15-30 minutes
MAX DOSING: 2mg/kg/day
Gastric pH monitoring may be needed I
select patients
Fentanyl(Sublimaze®
)
HIGH RISK MED
X X
Moderate
sedation
service
Only
Epidural
OK
X X 50 mcg/mL IVP
2000 mcg/100 mL
MAX:
2000 mcg/40 mL
5000 mcg/ 100 mL
Younger infants: Bolus: 1-2 mcg/kg/dose over 3-
5 mins; may repeat every 2-4 hrs. Doses >5
mcg/kg over 5-10 minutes.
Infusion: 1-2 mcg/kg bolus, then 0.5-1 mcg/kg/hr;
titrate to desired effect
Older infants and children 1-12 years: Bolus: 1-
2 mcg/kg/dose over 3-5 mins; may repeat every
30-60 mins. Doses >5 mcg/kg over 5-10 minutes.
Infusion: 1-3 mcg/kg/hr; titrate to desired effect.
Titrate to patient response using age
appropriate pain scale.Peak response 5-10
minutes post dose. Monitor respiratory rate,
blood pressure, heart rate, oxygen
saturation, and bowel sounds.
Rapid IV push may cause apnea/ muscle
and chest wall rigidity.
Fenoldopam
(Corlopam®
)
X X X 10 mg/mL vial
STD infusion
10mg/250NS
(40mcg/ml)
MAX Infusion
10 mg/100 mL NS
(100 mcg/mL)
Usual dosing: 0.1-0.8 mcg/kg/minute
Recommended MAX 1.6
mcg/kg/min
Titrate: 0.05-0.1 mcg/kg/minute q 10-20 minutes
Do not bolus or flush line.
Monitor HR, BP, EKG, renal function
Filgastim
(G-CSF, Neupogen®
)
X X S
C
X Dilute with D5W
only to a
concentration greater
than or
=15 mcg/mL (ie//300
mcg/
20-50 mLs).
Infusion over 15-30 minutes. Incompatible with
NS. Dosing: 5-10 mcg/kg/day
Do not administer 12 hrs before or after
radiotherapy.
Fluconazole
(Diflucan®
X X X Dilute to <2
mg/mL
Infusion: <6 mg/kg up to 400 mg over 1 hr
> 6 mg/kg over 2 hrs
Dosing: 3-12 mg/kg/day
Flumazenil
(Romazicon®
)
X X X 0.1 mg/mL 0.01 mg/kg (MAX dose: 0.2 mg) given over 15-30
seconds. May repeat after 45 seconds and then
every min to MAX total cumulative dose 0.05
mg/kg or 1 mg, whichever is lower. See dosing
table.
Monitor level of consciousness and
resedation, airway, BP, HR and RR.
Pediatric Guidelines for IV Medication Administration
NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist.
Version 9/28/2008 Barb Maas Pharm. D.
10
Approved For
Drug
ICU
ED
Telemetry
Required
Acute
Care
IV
P
IV
Infusion
Concen
tration Usual Dosing and
Administration
Comments
Folic Acid
(Folvite®
)
X X X X 0.1 mg/mL Infants: 15 mcg/kg/dose daily or 50 mcg daily
1-10 years: 1 mg/day initial; maintenance 0.1-0.4
mg/day
>11 years: Initially 1 mg/day; maintenance 0.5
mg/day
MAX rate: 5 mg/min
Monitor CBC with differential
Fosphenytoin
(Cerebyx®
)
Note:preferred over
phenytoin, write all doses
as PE equivalents
X X X 25 mg PE/mL Loading dose: 10-20 mg PE/kg not to exceed 3mg
PE/kg/min up to 150 mg PE/.minute
Maintenance: 4-8 mg PE/kg/day in 2-3 divided
doses
Doses of fosphenytoin are expressed in
phenytoin equivalents (PEs). Monitor ECG,
BP and RR during loading dose q 5 minutes
and for ≥ 30 minutes thereafter. Monitor
serum phenytoin levels, CBC, platelets,
glucose and LFTs.
Furosemide (Lasix®
) X X X X 10 mg/mL
100 mg/100 mL
IVP: MAX rate: 0.5 mg/kg/min up to 20
mg/minute
IVP; 0.5-2 mg/kg/dose every 6-12 hrs (MAX 6
mg/kg/day)
Infusion: 0.05-0.4 mg/kg/hr
Monitor I & O, electrolytes, renal function,
BP; in high doses monitor hearing.
Gentamicin X X X Dilute to
2 mg/mL
40mg/ml for IM
use
Infusion:Administerover 30 minutes. Peak levels
drawn 30 minutes after infusion completed.
Trough levels just before dose.
Infants > 7 days and children <5yrs: 2.5
mg/kg/dose every 8 hours; once daily dosing: 5-7.5
mg/kg/dose every 24 hrs
Children >5 years: 2-2.5 mg/kg/dose every 8
hours; once-daily: 5-7.5 mg/kg/dose every 24
hours.
Cystic Fibrosis: 5 mg/kg/dose q 12 hr or based on
previous dosing history.
For other dosing, please see reference for dosing
for specific indications.
Monitor serum levels, urine output, and
serum creatinine, drug levels.
Pediatric Guidelines for IV Medication Administration
NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist.
Version 9/28/2008 Barb Maas Pharm. D.
11
Approved For
Drug
ICU
ED
Telemetry
Required
Acute
Care
IVP IV
Infusion
Concen-
tration Usual Dosing and
Administration
Comments
Insulin Regular
(NovolinR®
)
HIGH RISK MED
X X
In Code
X X < 50kg: 25
units/50
mlsMAX:
100 units/
100 mL
IVP: Over 1 minute
Infusion: (regular insulin only)
DKA: Initial0.05-0.1 units/kg/hour up to 10 units/hr,
titrate to response.
> 50 kg: Normoglycemia in ICU..see adult protocol
Hyperkalemia: after calcium and bicarb administration,
infuse dextrose 0.5-1 gm/kg over 15-30 minutes followed
by insulin 0.1units/kg
Critical illness hyperglycemia: Review indications with
ICU attending. Usual starting dose 0.02-0.05 units/kg/hr
titrateto maintain blood glucose 80-140
Monitor urine sugar, blood sugar and
electrolytes. Drug may adsorb to IV bag
and tubing, when using new tubing,
prime, wait 30 mins, then flush tubing
prior to starting infusion.
Iron Sucrose
(Venofer)
X X X X May give
undiluted, or
as an infusion
of <
2mg/ml
Dosing: Refer to dosing references. Limited pediatric
dosing available.
IVP: Give each 100mg over 2-5 minutes (MAX 200mg)
Infusion: Each 100mg over 15-30 minutes
No test dose required.
May cause hypotension, esp w/ IVP.
.Hypotension may be rate related.
Ketamine
(Ketalar®
)
X X X
for
moderate
sedation,
MD
present
X X
Critical
care areas
only
20mg/ml,
50mg/ml
Infusion 200
mg/100 mL
NS
500mg/250ml
IVP: 0.25-2 mg/kg not to exceed 0.5 mg/kg/min.
Supplemental doses usually 1/3 to ½ of initial dose.
Infusion: Usual for analgesia/sedation or bronchospasm
5-20 mcg/kg/minute
Monitor RR, BP,HR, O2 sats.
Avoid in patients with increased ICP or
hypertension
Increases oral secretions.
Pretreatment with glycopyrrolate is
recommended if used for monitored
sedation.
Ketorolac (Toradol®
) X X X 15 mg/mL
30 mg/mL
IVP: Over 1-2 minutes
Bolus: (optional): > 2yrs. MAX 1 mg/kg up to 60 mg x 1
Maintenance: > 6 months 0.25-0.5 mg/kg/dose (MAX 30
mg given every 6 hours as needed, not to exceed 20
doses/treatment course.
Monitor for signs of pain relief, BUN,
creatinine, liver enzymes, blood loss and
urine output. Stop before surgery due to
prolonged bleeding
Labetalol
(Normodyne®
,
Trandate®
)
X X
See
comments
X
MD
avail-
able
X X
Critical
care areas
only
5 mg/mL
500 mg/250
mL
900 mg/250
mL
Bolus: 0.25-0.5 mg/kg/dose up to 1mg/kg
MAX rate: 0.25mg/kg over 3 minutes up to 10mg/minute.
Peak effect 5-15 minutes, duration 2-4 hrs.
Infusion: 0.4-3 mg/kg/hour
> 50kg: 2-6mg/minute
ECG monitoring ,HR, and BP
recommended during administration.
Monitor heart rate and blood pressure
every 5 mins until stabilized and every 15
mins during hypertensive episode up to
30 minutes post dose. Patient should
remain supine up to 3 hrs post dose.
Monitor blood pressure and heart rate
pre/post dosee
Infusion allowed in ICU
only.
Pediatric Guidelines for IV Medication Administration
NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist.
Version 9/28/2008 Barb Maas Pharm. D.
12
Approved For
Drug
ICU
ED
Telemetry
Required
Acute
Care
IVP IV
Infusion
Concen-
tration Usual Dosing and
Administration
Comments
Lepirudin (Refludan®
) X X X X IVP Dilute
to
5 mg/mL.
Infusion:
100 mg/250
mL
Requires hematology/oncology approval!
May contact anticoagulation service for dosing
recommendations and monitoring. Dosing adjustment
with renal impairment required.
Bolus: 0.4 mg/kg not to exceed 44 mg over 15-20
seconds.
Infusion (continuous): Initially 0.15 mg/kg/hr not to
exceed 16.5 mg/hr, titrate based on an aPTT.
Monitor aPTT, renal function, and for
signs and symptoms of bleeding.
Levetiracetam
Keppra®
X X X Dilute to <
15mg/ml
w/NS
Dosing:20-60mg/kg/day divided q12hrs MAX 4GM/day
Infusion:Over 15 minutes
Levofloxacin
(Levaquin®
)
X X X Dilute to 5
mg/mL
Infusion: Over 60-90 minutes
6 mths-5 yrs: 10 mg/kg/dose every 12 hours(limited
data).
Children> 5 yrs: 10 mg/kg/dose every 24 hrs (MAX
dose: 500 mg)
Adolescents/Adults: 250-750 mg IV q 24 hrs
Too rapid infusion may cause
hypotension.
Monitor renal, hepatic, and
hematopoietic function periodically;
number and types of stools/day for
diarrhea.
Levothyroxine
(Synthroid®
)
X X X X May dilute
w/NS to 40
mcg/mL
(5 mLs/200
mcg)
IVP: Dilute vial with 5 mL NS, use immediately,
administer over 2-3 minutes. Discard remainder.
See age specific initial dosing, or per endocrine; IV
form is 50% of PO recommendation.
IV dose usually 50% of oral dose.
Monitor T4, TSH, heart rate, clinical signs
of hypo- and hyperthyroidism.May be
used as a continuous infusion prior to
organ donation—
Lidocaine X X X
Code
only
X X 20 mg/mL
IVP
2 grams/250
mL
Load: 1-1.5 mg/kg over 2-4 minutes up to MAX 0.7
mg/kg/min up to 50 mg/minute, MR 0.5-1 mg/kg Q 5-10
minutes X 2
Infusion: 20-50 mcg/kg/min MAX up to 6 mg/min in
adults (usual 1-4 mg/min).
Monitor EKG, HR, BP.UO, LFT’s and
serum concentrations with continuous
infusion & IV site for thrombophlebitis if
via peripheral administration. Contra-
indicated with heart block. Lower dosing
may be required with severe CHF or
hepatic impairment.
Linezolid (Zyvox®
) X X 2 mg/mL Infusion: Over 30-120 minutes
< 12yo: 10 mg/kg/dose q 8-12 hrs up to 600 mg/dose
>12yo/adult: 400-600 mg q 12 hrs
Requires ID approval. Avoid
foods/beverages high in tyramine to
avoid hypertension (consult nutrition)
Pediatric Guidelines for IV Medication Administration
NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist.
Version 9/28/2008 Barb Maas Pharm. D.
13
Approved For
Drug
ICU
ED
Telemetry
Required
Acute
Care
IVP IV
Infusion
Concen-
tration Usual Dosing and
Administration
Comments
Lorazepam (Ativan®
) X X X X
ICU only
IVP: May be
diluted to 1
mg/mL w/ NS
MAX 4 mg/mL
Infusion
50 mg/50 mL
250 mg/250 mL
IVP: Not to exceed 0.05 mg/kg over 2-5 minutes up to 2
mg/minute
Dosing:0.02-0.1 mg/kg/dose (given every 4-8 hours as
needed). Initial MAX 2 mg for sedation, 4 mg for
seizures.
Infusion:0.05-0.15 mg/kg/hr up to 2 mg/kg/day or 100
mg/DAY whichever is less. (see comments)
Usual adult initial dosing 0.5-2mg/hr
Monitor respiratory rate, blood pressure,
heart rate and symptoms of anxiety.
Monitor for phlebitis/ infiltration with
peripheral access.
With normal renal function, doses
approaching 3 mg/kg/day( up to 170
mg/24 hrs should be monitored for
propylene glycol toxicity
(hyperosmolarity, lactic acidosis, renal
toxicity) . Other adult studies have
recommended doses not to exceed
1mg/kg/day .Patients with renal
compromise should switch to oral
lorazepam, seek alternative agents, or
monitor for toxicity using lower dosing.
Infusion ICU only.
Magnesium Sulfate X X X PEDI STD:
1 GM/25 mLS
(40 mg/mL)
ADULT:
1 gram/50 mL
2 grams/50 mLs
Asthma: 25-75 mg/kg over 20 minutes
Torsades/PALS: 25-50 mg/kg over 10-20 minutes
Repletion(non-acute): 25-50 mg/kg/dose infused over 2-4
hrs
Can cause hypotension with too rapid
infusion.Monitor serum magnesium, deep
tendon reflexes, respiratory rate and
blood pressure.
1 gm=8.12 mEq=98.6 mg Magnesium
Mannitol (Osmitrol®
) X X X
Low
dose
X 12.5 grams/ 50
mL (25%)
50 grams /250
mLs (20%)
IVP: 0.2gm/kg over 3-5 minutes
Infusion: 0.25-1 gm/kg over 15 -60 minutes.
Requires inline filter.
Central line preferred. Monitor for extravasation.
Evaluate dose for crystal formation prior
to administration. In-line <5 micron
filter should always be used with
concentrations >20%. . Central line
preferred. Extravasation may cause
edema and necrosis. Monitor renal
function, daily I & Os, serum
electrolytes, serum and urine osmolality.
Meperidine
(Demerol®
)
HIGH RISK MED
X X X
slow
X Dilute to <
10 mg/mL
IVP slow: 1 mg/kg/dose over 3-5 minutes every 3-4
hours as needed; administer over ≥ 5 mins (do not exceed
25 mg/min) MAX 100 mg/dose, up to 6 mg/kg/day.
Avoid repeated doses with renal dysfunction.
Restricted use to post-anesthesia
shivering and rigors. Monitor
respiratory and cardiovascular status and
level of sedation, and pain.
Meropenem
(Merrem®
)
X X X X Dilute to 20
mg/mL
IVP: Over 3-5 minutes
Infusion: Over 15-30 minutes
Dosing: 20-40 mg/kg/dose q 8hrs up to
2 Gm/dose
Requires ID approval.
Pediatric Guidelines for IV Medication Administration
NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist.
Version 9/28/2008 Barb Maas Pharm. D.
14
Approved For
Drug
ICU
ED
Telemetry
Required
Acute
Care
IVP IV
Infusion
Concen-
tration Usual Dosing and
Administration
Comments
Methadone
(Dolophine®
)
HIGH RISK MED
X X X 10 mg/mL
Dilute w/ NS
to volume
needed to
infuse over 15
minutes
Infusion: Over 5-15 minutes
Initial Dose in narcotic naïve patients: 0.05-1
mg/kg/dose up to 10 mg/dose q 6-12 hrs(1st
24 hrs) , as
drug accumulates over 24-96 hrs, , dosing frequency may
need to be reduced to q 12-24 hrs.
Monitor RR, HR, BP, sedation and pain
levels. Abstinence scoring is used for
withdrawal. Monitor for QT
prolongation in patients with risk factors.
Methyldopa
(Aldomet®
)
X X Dilute with
D5W to <
10 mg/mL
Initial: 2-10 mg/kg/dose every 6-8 hours. MAXdose 1
gm, Daily dose: 65 mg/kg or 3 grams, whichever is less.
Infusion:Administer slowly over 30-60 mins
Onset: 4-6 hrs
Duration: 10-16 hrs
Monitor blood pressure, CBC with
differential, hemoglobin, hematocrit, and
liver enzymes.
Methylprednisoloneso
dium succinate
(Solu-Medrol®
)
X X X
<1.8
mg/
kg
X 40 mg, 125
mg,
500 mg & 1
g vial
Dosing: 0.5-2 mg/kg/day as high as 30 mg/kg depending
on indication.
IVP: <1.8 mg/kg up to 125 mg over 3-15 minutes
Infusion:May dilute each 1gm dose in a minimum of 100
mls NS (10mg/ml) (exception: spinal cord injury protocol
< 2mg/kg: administer over 1-3 minutes
>2 mg/kg: administer over 15-30 mins
15 mg/kg up to 500mg: Administer over >+30 minutes
>15 mg/kg up to 1 Gm: Administer over 1 hour
Caution: Methylprednisoloneacetate is
for IM use only. Monitor blood pressure,
serum glucose and electrolytes.
Metoclopramide
(Reglan®
)
X X X
Low
dose
X 5 mg/mL Dosing: 0.1-1 mg/kg/dose q 4-6 hrs
IVP: Low dose 0.1 mg/kg up to 10 mg over 1-2 minutes
Infusion over 15-30 mins
(MAX rate: 5 mg/min)
Consider pretreatment with
diphenhydramine for doses > 0.25
mg/kg. Monitor for EPS. Too rapid
administration may cause anxiety
Administer diphenydramine for patients
Metronidazole
(Flagyl®
)
X X X 5 mg/mL Dosing: 20-45 mg/kg/day up to 4 gms/day divided every
6 or 8 hrs
Infusion: Over 60minutes
Do not refrigerate. Doses other than 500
mg will be found in the Pyxis drop-off
box.
Midazolam
(Versed®
)
X X
Per
monitored
sedation
protocol
X
for
moderate
sedation,
MD
present
X X <50kg:
50mg/100ml
MAX:
100 mg/100
mL
1 mg/mL,
5 mg/mL
6 months-5 years: Initial 0.05-0.15 mg/kg
(MAX total dose: up to 0.6 mg/kg up to 6 mg)
6-12 years: 0.025-0.05 mg/kg
(MAX total dose: up to 0.4 mg/kg up to 10 mg in non-
intubated patients)
IVP: over 2-5 mins, longer for higher doses
Infusion: 0.06-0.4 mg/kg/hour MAX 0.4 mg/kg/hr
Monitor level of sedation, respiratory
rate, blood pressure, heart rate and
oxygen saturation
Pediatric Guidelines for IV Medication Administration
NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist.
Version 9/28/2008 Barb Maas Pharm. D.
15
Approved For
Drug
ICU
ED
Telemetry
Required
Acute
Care
IVP IV
Infusion
Concen-
tration Usual Dosing and
Administration
Comments
Milrinone lactate
(Primacor)
X X X 1 mg/mL 10
mLs
Infusion:
20 mg/100
mL
Load: 25-100mcg/kg over 15 mins
Infusion: 0.2-1.2 mcg/kg/min
Monitor EKG, BP, HR, UO platelet
count, potassium, renal function, signs
and symptoms of HF
Morphine Sulfate
HIGH RISK MED
X X X
slow
X 2, 4, 10
mg/ml
PCA 1, 5
mg/mL
INF: 1mg/ml
100 or 250ml
MAX: 500
mg/ 100 mL
Bolus: 0.05-0.1 mg/kg/dose up to initial MAX 10 mg
over 5-30 mins
Infusion: Initial 0.005-0.15 mg/kg/hr; titrate to patient
pain response and tolerance.
Monitor HR, RR, BP, oxygen saturation,
pain relief and level of sedation.
Nafcillin
(Nafcil®
)
X X X
slow
X 20 mg/mL
1-1.5 gm/
50 mLs
1.6-2
gm/100 mLs
Dosing: 50-200 mg/kg/day divided q 4 or q 6 hrs
MAX 12 gms/day
IVP: Over 5-10 minutes
Infusion: Over 30-60 minutes
Monitor for burning, extravasation,
phlebitis
Nalbuphine (Nubain®
) X X X
slow
X 10 mg/mL
20 mg/mL
Premed: 0.1-0.2 mg/kg MAX 20gm
Analgesia: 0.05-0.15 mg/kg every 3-6 hours as needed.
Initial MAX 10 mg
MAX: 20 mg/dose up to 160 mg/day
IVP: Administer over 3-5 mins
Infusion:Over 15 mins
Monitor relief of pain, respiratory and
mental status, and blood pressure.
Pediatric Guidelines for IV Medication Administration
NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist.
Version 9/28/2008 Barb Maas Pharm. D.
16
Approved For
Drug
ICU
ED
Telemetry
Required
Acute
Care
IVP IV
Infusion
Concent
ration Usual Dosing and
Administration
Comments
Naloxone (Narcan®
) X X X X 0.4 mg/
mL
IVP dilution:
< 40 kg 0.1
mg in
9.75 mLs NS
=(0.01mg/mL)
> 40 kg 0.4 mg
in
9 mLs NS=
(0.04mg/mL)
Infusion:
4 mg/100
mLs NS
(0.04 mg
=40 mcg/
mL)
Post anesthesia narcotic reversal:
Narcotic naïve: 0.005-0.01 mg/kgIVP q 2-3 mins as
needed
Opiate dependent: 0.001-0.002 mg/kg IVP q 2-3 mins as
needed(1/10th
-1/5th
usual dose to prevent acute
withdrawal)
IVP: Over 30 seconds
Narcotic-induced pruritis:
0.25-2 mcg/kg/hr; increase by0.25- 0.5 mcg/kg/hr every
few hours as needed
Opiate intoxication: (narcotic naïve)
<20 kg: 0.1 mg/kg every 2-3 minsprn
>20 kg: 2 mg/dose every 2-3 minsprn
Opiate dependent: (1/10th
-1/5th
usual dose to prevent
acute withdrawal)
Infusion: calculate initial dose/hour based on effective
intermittent dose used and titrate; range: 2.5-160
mcg/kg/hour
Monitor respiratory rate, heart rate, and
blood pressure.
The duration of action of naloxone is
shorter than most opiates (20-30
minutes). Patients who receive naloxone
should be monitored for reoccurance of
respiratory depression.
Patients with acute pain will require
careful titration to maintain analgesia
while reversing respiratory depression.
Neostigmine
(Prostigmin®)
X X X
slow
0.5 mg/ml
1 mg/mL
Non-depolarizing NMB reversal: with atropine or
glycopyrrolate
Infants: 0.025-0.1 mg/kg/dose
Children: 0.025-0.08 mg/kg/doseMAX/DOSE (see adult)
Myasthenia gravis treatment:
0.01-0.04 mg/kg every 2-4 hoursMAX/DOSE (see adult)
Adult: 0.5-2.5 mg, MAX 5 mg
IVP: Administer over several minutes up to 0.5mg/min
Atropine or glycopyrrolate recommended
prior to neostigmine. Epinephrine should
be available. Monitor HR, BP,RR,
muscle strength.
Nicardipine
(Cardene)
X X X Standard/Periph
eral- Add 25
mg to 250 mLs
NS (0.1mg/mL)
MAX/Central:
Add 100 mg to
60 mLs NS (1
mg/mL)
Infusion: IF< 50 kg Initial 0.5-5 mcg/kg/minute
If >50 kg: 2.5-15 mg MAX: 15 mg/HOUR.
Titrate q 5-30 minutes
Monitor blood pressure and heart rate
Nitroglycerin X X X 100 mg/250
mLs
Infusion: If < 50 kg 0.25-1 mcg/kg/min titrate by 0.5-1
mcg/kg/min every 3-5 mins as needed. MAX 20
mcg/kg/min
>50 kg:5 mcg/min, titrate by 5-10 mcg/minq 3-5 mins up
to 300 mcg/min
Monitor blood pressure and heart rate.
Protect the drugfrom light.
Pediatric Guidelines for IV Medication Administration
NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist.
Version 9/28/2008 Barb Maas Pharm. D.
17
Approved For
Drug
ICU
ED
Telemetry
Required
Acute
Care
IVP IV
Infusio
n
Concentrati
on Usual Dosing and
Administration
Comments
Nitroprusside
(Nipride)
X X X 100 mg/
250 mL
Infusion: 0.3-5 mcg/kg/min Titrate by 0.1 mcg/kg/min q
2-3 minutes
MAX 10 mcg/kg/min
Protect the drugfrom light. Do not use
if blue-green in color. Monitor blood
pressure, heart rate, cyanide and
thiocyanate toxicity; monitor acid-base
status as acidosis can be early sign of
cyanide toxicity; monitor thiocyanate
levels if infusion needed for >3 days or
dose >4 mcg/kg/min or in renal
dysfunction; monitor cyanide levels in
hepatic dysfunction.
Norepinephrine
(Levophed)
X X X <10 kg 8
mg/250
mL
10-50 kg +
MAX
16 mg/250 mL
>50 kg4
mg/250
mL
Infusion:Initial 0.05-0.1 mcg/kg/min.
Titrate by 0.1-0.2 mcg/kg/minute every 5 minutes till
desired effect or toxicity
Recommended MAX 2 mcg/kg/min
Monitor blood pressure, heat rate, urine
output, and peripheral perfusion. Central
line preferred.
Octreotide Acetate
(Somatostatin)
Note: not to be
confused with
Sandostatin LAR
Depot IM injection
X X X X 50, 100, 500
mcg vial for
SC/IV admin
Standard
infusion:
500 mcg in 100
mLs
NS/D5W (5
mcg/mL)
REFRIGERAT
ED
Hypoglycemia/Antisecretory: 2-10 mcg/kg/day divided
q 8 or 12 hours or as continuous infusion: titrate to patient
response by increasing dose or interval;
GI bleed/esophageal varices:0.5-1 mcg/kg bolus, then 1
mcg/kg/hour continuous infusion; titrate to
response(usual adult 25-50 mCG/HR)
MAX DOSE: 1500 mcg/day
SC: usual bolus route
IV: infuse over 15-30 mins in NS
IVP: over 3 minutes
Monitor baseline and periodic ultrasound
evaluations for cholelithiasis, blood
sugar, thyroid function tests, fluid and
electrolyte balance.
Ondansetron
(Zofran)
X X X X 2 mg/mL Chemo induced N/V:
Children: 0.15 mg/kg/dose MAX 0.45 mg/kg/day up to
32 mg
Nausea/Vomiting:
Children >2 yrs <40 kg: 0.1 mg/kg
Children >40 kg: 4 mg
IVP: undiluted over 1-5 minutes
Infusion: over 15 minutes in NS/ D5W
Monitor blood pressure and heart rate.
May cause headache.
Pediatric Guidelines for IV Medication Administration
NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist.
Version 9/28/2008 Barb Maas Pharm. D.
18
Approved For
Drug
ICU
ED
Telemetry
Required
Acute
Care
IVP IV
Infusion
Concentr
ation Usual Dosing and
Administration
Comments
Pamidronate
(Aredia)
X X X Prepared by
pharmacy.
Volume
varies by
dose.
Hypercalcemia/osteopenia:0.5-1 mg/kg (MAX dose of
90 mg). Do not redose within 7 days.
Infusion: Over 2-24 hrs. (Longer infusion times ↓ the
risk of nephrotoxicity.) Infuse in dedicated line.
Thrombophlebitis. Monitor serum
creatinine prior to each dose, urine
output, serum electrolytes, phosphate,
magnesium, hemoglobin, hematocrit,
CBC with differential.
Pentobarbital
(Nembutal)
X X
Continuous
Infusion
Or per
moderate
sedation
protocol
X
for
moderate
sedation,
MD
present
X
slow
X 50 mg/mL
Infusion:
2500 mg/
50 mls
(50 mg/ml)
Sedation:
Children >6–18 mths: 1-3 mg/kg
Children >18 mths: 2 mg/kg, then 1-2 mg/kg every 5-10
minsuntil adequate sedation
MAX: 100 mg/dose
*IVP: slowly (<1 mg/kg/min up to 50 mg/min) Used
only with conscious sedation monitoring or in ICU/ER.
IV: Over 10-30 minutes. May be further diluted to no
less than 5 mg/mL with NS. Do not use unless solution is
clear.
Pentobarbital Coma:
Load: 15-35 mg/kg over 1-2 hrs
Infusion: 1-5 mg/kg/hr viadedicated central line
preferred. MAX: 10 mg/kg/hr
Monitor vital signs, blood pressure,
respiratory status, cardiovascular states,
CNS status.
Monitor for
thrombophlebitis/extravasation.
Central linr preferred and particulate
filter required with continuous infusions.
Check infusion regularly to monitor for
precipitation.
For pentobarbital coma, also monitor
EEG bursts..
Phenobarbital
(Luminal)
X X X 65 mg/mL
130mg/ml
Anticonvulsant:
Load: 15-18 mg/kg at 1-2 mg/kg/minute (MAX 60
mg/minute).
Maintenance:
IV: < 1 mg/kg/min up to 30 mg/minute
Infants: ≤ 5 mg/kg/day in 1-2 doses
1-5 yrs: 6-8 mg/kg/day in 1-2 doses
5-12 yrs: 4-6 mg/kg/day in 1-2 doses
>12 yrs: 1-3 mg/kg/day in 1-2 doses
Monitor CNS status, seizure activity,
LFTs, CBC, renal function, serum
concentrations, respiratory rate, heart
rate, blood pressure,
Phenylephrine
(Neo-synephrine)
X X X
ICU/
ER
only
X (for<10 kg)
5 mg/250
mL
(10-+kg)
10 mg/250
mL
MAX
CONCENTR
ATION
60 mg/250
mL
Hypotension/Shock:
Usual 0.1-0.5 mcg/kg/min; titrate to desired effect
PSVT: 5-10 mcg/kg over 20-30 seconds
(Adult: 0.25-0.5 mg)
Monitor heart rate, BP/MAP, CVP.
Central line preferred
Pediatric Guidelines for IV Medication Administration
NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist.
Version 9/28/2008 Barb Maas Pharm. D.
19
Approved For
Drug
ICU
ED
Telemetry
Required
Acute
Care
IVP IV
Infusion
Concent
ration Usual Dosing and
Administration
Comments
Phenytoin sodium
(Dilantin®
)
Note:Fosphenytoin should
be used in children instead
phenytoin
X X X 50 mg/mL
(mustdil-
ute to 1-5
mg/mL in
NS)
Acute Seizures
Load: 15-20 mg/kg in a single or divided doses
MAXinfusion rate:
Neonates: 0.5 mg/kg/min
Children: 1-3 mg/kg/min not to exceed 50 mg/min
Maintenance: 4-8 mg/kg/day in 2-3 divided doses
Loading doses: Monitor HR/ BP and RR
during loading dose q 5 minutes and for
≥ 30 minutes thereafter. Telemetry
monitoring recommended if patient has
significant underlying cardiac disease.
Particulate filter required. Check for
extravasation.
Monitor serum levels, CBC, LFTs, and
blood pressure.
Phosphate as
Sodium Phosphate
Each 1 Meq Na+ = 0.75mM
Phos, 1mMPhos =
1.33Meq Na+
Potassium Phosphate
Each mMPhos=
1..47 meq K+
1 meq K+ = 0.68mM Phos
X X X All IV doses
prepared by
pharmacy.
Volume
depends on
dose and
whether via
central or
peripheral
adminis
tration.
Dosing in MMols: Hypophosphatemia:
Phos> 2: 0.05-0.1 Mm/kg up to 15mM
Phos 1-2 mM/dl- 0.16-0.25mM/kg up to 30Mm
Phos< 1mM/dl: 0.25-0.4mM/kg up to
0.6mM/kg to MAX 30mM/dose or 45mM/day
IV infusion: Doses < 0.5mM/kg or 30mM over 4 hrs.
Doses >=0.5mM/kg or 30Mm over 6 hrs
Maximum Concentration:
Peripheral 30mM Phos/L (1.5mM per
50mls Central: 30mM Phos/250
mls=
6mM per 50 mls
INFUSION: Intermittent doses over 4-6
hrs. MAX: 0.06mM/kg/hr
**in pediatrics, order doses in 50, 100,
150, 250, 500, OR 1000 ml volumes.
**caution: for Kphos orders written in
mM
be aware of K+ dose pt will also be
recieving
Phytonadione (Vitamin
K, Mephyton®
)
X SC/IM
only
X
(ICU/
OR/ER
only)
10 mg/mL
1 mg/mL
*SC, IM, or PO preferred.
Dose: 1-10 mg, Usual 1-2.5 mg
IV(restricted) : Dilute w/ NS to volume needed to
administer over 15-30 minutes. (see comments)
Monitor for potential hypersensitivity
reactions, flushing. Monitor BP, HR,
RR.@ baseline then q 5 min during
infusion .
Piperacillin/Tazobactm
(Zosyn®
)
X X X 60 mg
piperacillin
and7.5 mg
tazobactam/
mL
2.25 g/50 ml
3.375 g/50
mL
4.5 g/50 mL
Infants <6 mths: 150-300 mg of piperacillin
component/kg/day in divided doses every 6-8 hours
>6 mths: 200-350 mg of piperacillin component/kg/day
in divided doses every 6-8 hours.
CF: 350-450 mg/kg/day divided q4h or q6 hrs MAX
4.5gm/dose
IV:Over ≥ 30 minutes
Monitor serum electrolytes, bleeding
time especially high dose or w/ renal
impairment. periodic tests of renal,
hepatic, and hematologic function.
Potassium Chloride
HIGH RISK MED
X X
For IV doses
exceeding
0.3meq/kg/hr
up to
10meq/hr
X X Pedi: 0.4
mEq/mL-25
mL vials for
central bolus
doses (10
mEq)
20 mEq/50
ml bags
Maintenance: Usual daily dose 2-5mEq/kg/day
(Adult usual: 40-80 mEq/day.)
Hypokalemia: Dosing depends on severity, etiology, and
renal function. See comments on individual dosing
limitations.
MAX: Peripheral 0.06 mEq/mL (60
mEq/L)
Central 0.4mEq/mL
RATE: non-telemetry <0.3 mEq/kg/hr
up to 10 mEq/hr
Telemetry-0.6 mEq/kg/hr up to
20 mEq/hr
Monitor serum potassium, glucose,
chloride, pH, urine output if indicated
Pediatric Guidelines for IV Medication Administration
NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist.
Version 9/28/2008 Barb Maas Pharm. D.
20
Approved For
Drug
ICU
ED
Telemetry
Required
Acute
Care
IVP IV
Infusion
Concen
tration Usual Dosing and
Administration
Comments
Prochlorperazine
(Compazine®
)
X X X X 5 mg/mL Antiemetic: Children >10 kg:
Dose IV/IM: 0.1-0.15 mg/kg/dose every 6-12 hours
(MAX: 10mg/dose)
IV: May be further diluted in a sufficient volume with
NS and administered over 15-30 minutes
IVP: Administer at MAX rate of 0.1
mg/kg/minute(MAX 5 mg/min)
In children < 5yo, reserve this agent for
patients who are unresponsive to other
alternatives due to the higher risk of
extrapyramidal effects. Alternative
routes to IV preferred.
Monitor for extrapyramidal reactions,
hypotension, and signs of extravasation.
Promethazine
(Phenergan®
)
X X X 25 mg/mL Not recommended in patients < 2yrs of age due to
significant respiratory depression.
For use in children >2 years. Oral/rectal routes
preferred.
Antiemetic: 0.25-1 mg/kg (MAX dose: 25 mg in
children, 50 mg in adolescents) 4-6 times/day as needed.
Begin with lowest dose.
Usual Adult Dose: 12.5-25 mg
IV: Further diluted 1:10 (v/v) or greater in NS to
minimize extravasation injuryand administered over 10-
20 minutes.
Monitor for extrapyramidal reactions,
respiratory depression, hypotension, and
signs of pain and extravasation.
Propofol
(Diprivan®
)
X X X
Moderate
sedation
service
+
moderate
sedation
RN
X X 10 mg/mL
200 mg/20
mLs
500 mg/50
mLs
1000 mg/100
mLs
Do not dilute
to less than 2
mg/mL with
D5W (even
via y-site)
due to
emulsion
instability.
ICU SEDATION: (> 24 hrs)
Infusion 5-50 mcg/kg/minute. Titrate upward by 5-10
mcg/kg/min q 5-10 minutes to desired level of sedation
and as hemodynamically tolerated.
PRN boluses w/ infusion: 0.25-1 mg/kg up to 50 mg/dose
MAX MAINTENANCE ICU sedation rate not to exceed
50 mcg/kg/minute.
MONITORED PROCEDURAL SEDATION-
Initiation:
IVP: 0.5-3 mg/kg over 20-30 seconds
OR
0.25-0.5 mg/kg/dose MAX 40 mg/dose
q 10 seconds
OR
100-300 mcg/kg/min x 3-5 minutes, then
titrate to desired effect
Maintenance infusion: usual 50-300 mcg/kg/min
Avoid in patients with significant peanut/
soy/ or egg allergies.
Monitor respiratory rate, blood pressure,
heart rate, oxygen saturation, ABGs,
depth of sedation, serum lipids or
triglycerides if use is >24 hours.
To minimize pain at injection site,
administer through central line or large
peripheral veins.
Use filter with pore size > 5 microns.
Insure strict aseptic technique. Unused
drug and tubing must be discarded every
12 hrs to minimize risk of infection.
Drug transferred to syringes must be
discarded within 6 hrs.
In patients receiving parenteral nutrition,
consider amount of fat provided by
propofolemulsion in nutrition goal.
Pediatric Guidelines for IV Medication Administration
NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist.
Version 9/28/2008 Barb Maas Pharm. D.
21
Approved For
Drug
ICU
ED
Telemetry
Required
Acute
Care
IVP IV
Infusion
Concen
tration Usual Dosing and
Administration
Comments
Propranolol
(Inderal®
)
X X X 1 mg/mL
May dilute
each MG in
10-50 mLs
NS
0.01-0.025 mg/kg slow IV over 10 mins (MAX dose: 0.5
mg/dose for infants and 1 mg/dose for children)
Usual adult dose: 1-3 mg slow over 10 minutes, not to
exceed 1 mg/minute
Conversion from PO to IV unpredictable
due to first pass metabolism.
Recommend alternative IV
hypertensive’s (labetolol or metoprolol
for BP control)
Monitor blood pressure, CVP, and EKG
Protamine Sulfate X X X X 10
mg/mL*
* After vial
reconstitutio
n with
5 mLSWI.
May be
further
diluted with
NS or D5W.
Dose determined by the most recent time and dosage of
heparin or low molecular weight heparin, (please see
dosing references)
MAX dose: 50 mg
MAX rate: IVP < 5 mg/minute
Use cautiously in pts with fish or
protamine allergies.
Hypotension, bradycardia and flushing
may be infusion rate related reactions.
Continue to monitor coagulation, blood
pressure, and cardiac status.
Rasburicase
(Elitek®
)
X X X 1.5 mg/mL
Requires
oncology
attending
approval.
Prepared by
chemo
pharmacy in
10-50 mLs
NS.
0.15-0.2 mg/kg/dose MAX: 0.4 mg/kg/day for up to 5-7
days.
Infuse over 30 minutes. Flush with NS pre- and post
infusion.
Monitor for potential anaphylaxis.
Dedicated line preferred. Do not shake
or filter.
Recommended as a single course of
therapy.
Rho(D) Immune
Globulin (WinRho®
)
X X X Approx 230-
240
units/mL, as
0.5, 1.3, 2.2,
4.4, 13 mL
vials
Does not
require
further
dilution.
Dose for ITP: 25-75mcg/kg slow IV over 3-5 minutes Hgb should be >8 gm/dl prior to
administration.
May be further diluted with NS.
Rocuronium
HIGH RISK MED
X X 1 mg/mL Infants: 0.5 mg/kg/dose, repeat every 20-30 minutes as
needed
Children: Initial: 0.6 mg/kg/dose with repeat doses of
0.075-0.125 mg/kg every 20-30 mins to desired effect
Infusion: 10-12 mcg/kg/min
Monitor peripheral nerve stimulator
measuring twitch response, heart rate,
blood pressure and assisted ventilator
status.
Pediatric Guidelines for IV Medication Administration
NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist.
Version 9/28/2008 Barb Maas Pharm. D.
22
Approved For
Drug
ICU
ED
Telemetry
Required
Acute
Care
IVP IV
Infusion
Concen
tration Usual Dosing and
Administration
Comments
Sodium Bicarbonate X X X X 5 mEq/10
mL(4.2%)
(=0.5
mEq/mL)*
*Preferred
in infants
and small
children
50 mEq/50
mL(8.4%)
(=1
mEq/mL)
Please see reference for dosing for specific indications.
Code: 1 mEq/kgdose over 3-5 minutes
Non-Code:Not to exceed 1 mEq/kg/hr up to 50 meq/hr
Prevention of tumor lysis: 120-200 mEq/m2
/day
Monitor serum electrolytes, urinary pH
and arterial blood gases if indicated, pain
and phlebitis with peripheral
administration.
Hyperosmolar: Central line preferred, or
dilute 1 mEq to 2 or 3 mLs for peripheral
administration
Verify compatability before Y-site
administration with other drugs.
Sodium Chloride 3%
(hypertonic)
0.513meq Na+/ml
X X Symptomatic IsovolemicHyponatremia:
uptp4mls/kg/dose over 15 minutes. (equivalent to ~ 12-
15mls/kg NS).
HypovolemicHyponatremia:Use NS fluid bolus
ICP Management: 1-4 mls/kg undiluted over 15 minutes
Central line preferred. For correction of
acute hyponatremia, avoid rapid
increases in serum sodium. In
symptomatic patients or is serum sodium
< 120meq/L, target for an initial increase
of 4-6meq/L, not to correct beyond 12-
15meq/L per 24hrs
Sodium Chloride
23.4%(hypertonic)
4 meq Na+/ml
X X
Concentrated
electrolyte
May not be
stored at
bedside or in
pyxis.
Available for
STAT
Call
pharmacy.
ICP Management Adults: 15-30mls undiluted over 15
minutes
Central line required. Monitor serum
Na+ and osmolar gap.
Succinylcholine
HIGH RISK MED
X Preferred Emergency
intubation
only
X 20 mg/mL
Does not
require
futher
dilution.
REFRIGER
ATE
Initial: 1-2 mg/kg (MAXtotal dose: 150 mg)
Administer over 30 seconds.
Maintenance: Avoid repeated dosing. 0.3-0.6 mg/kg
every 5-10 mins as needed. For short-term administration
due to risk of hyperkalemia.
Avoid in any patients with
neuromuscular disorder/acute burns
secondary to risk of hyperkalemia.
Avoid with increased ICP.
Because of the risk of malignant
hyperthermia, use of continuous
infusions is not recommended. Monitor
heart rate and rhythm, serum potassium,
assisted ventilator status, muscle
twitching.
Sulfamethoxazole and
Trimethoprim
(Bactrim, Septra®
)
X X X 16 mg/mL
TMP
80 mg/mL
SMZ
Note:dosin
g based on
TMP
component
Evaluate risk-benefit in infants<2 months:. Avoid use if
infant has hyperbilirubinemia or in patients with renal
failure.
Mild-Mod infections: 6-12 mg TMP/kg/day divided
every 12 hours
Serious infections: 15-20 mg TMP/kg/day divided every
6-8 hours.
Administer MAX concentration of 1:10 dilution (each 5
mL of drug added to no less than 50 mLsof D5W) over
60-90 minutes. Complete infusion within 2 hrs of
dilution due to limited stability.
Use a particulate filter. Monitor for
precipitates, especially in maximally
concentrated dilutions.
Monitor for rash, phlebitis, urine output,
CBC, renal function tests.
Pediatric Guidelines for IV Medication Administration
NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist.
Version 9/28/2008 Barb Maas Pharm. D.
23
Approved For
Drug
ICU
ED
Telemetry
Required
Acute
Care
IVP IV
Infusion
Concent-
ration Usual Dosing and
Administration
Comments
Terbutaline
(Brethine®
)
X X X X 1 mg/mLvials
Infusion: 20
mg/100 mLs
NS (200
mcg/mL)
Prepared by
pharmacy
unless
emergent.
See infusion chart
Bolus: 2-10 mcg/kg (administer from infusion bag0.01-
0.05 mls/kg over 5-10 mins bag)
Infusion:0.1-6mcg/kg/minute (MAX 10
mcg/kg/minute).Titrate by increments of 0.1-0.2
mcg/kg/min every 30 mins to desired effect.
Monitor heart rate, blood pressure,
respiratory rate, serum potassium, CPK,
EKG, and blood gases if applicable.
Tobramycin (Nebcin®
) X X X Dilute to
< 5 mg/mL
Infusion:Administerover 30 minutes. Peak levels drawn
30 minutes after infusion completed. Trough levels just
before dose.
Infants > 7 days and children <5yrs: 2.5 mg/kg/dose
every 8 hours; once daily dosing: 5-7.5 mg/kg/dose every
24 hrs
Children >5 years: 2-2.5 mg/kg/dose every 8 hours;
once-daily: 5-7.5 mg/kg/dose every 24 hours.
Cystic Fibrosis: 5 mg/kg/dose q 12 hr or based on
previous dosing history.
For other dosing, please see reference for dosing for
specific indications.
Monitor serum levels, urine output, and
serum creatinine
Tromethamine
(THAM®
)
X X X 18 gm/500
mLs
(0.3
mM/mL)
1 mEq=1
mm=
120 mg per
3.3 mLs
Neonates: 1 mL/kg for each pH unit below 7.4.
Infants/Children/Adults:
Dose (in mLs)= kg X base deficit (mEq/L) X 1.1
up to 13.9 mLs/kg/dose
Infusion:Over≥ 1 hr.
0.7-1 mL/kg/hr MAX 23 mls/kg/day.
Acute Acidosis: 25% of dose over 5-10 minutes followed
by remainder over 1 hr.
Intended for short-term use.
Central line or large peripheral vein
(pH10.5) preferred. Monitor for
extravasation, tissue injury, thrombosis.
Monitor for respiratory depression,
hypoglycemia, hyperkalemia, renal
functiom, serum pH, ABG’s,
hyperosmolarity
Vancomycin
(Vancocin®
,
Vancoled®
)
X X X Dilute to <5
mg/mL
Central: <
10mg/ml per
request if fluid
restricted
Infusion:Over 60-90 minutes, slower if pt experiencing
red-man syndrome (histamine-like reaction).
< 7 days: 10-15 mg/kg every 12 hours
> 7 days: 10-15 mg/kg every 6-8 hrs
Infants> 1 month, children: 40-60 mg/kg/day divided
every 6-8 hours up to initial MAX 1.5 gm/dose up to 4
gm/day. Adjust for renal dysfunction.
Monitor periodic renal function tests,
urinalysis, serum vancomycintrough
levels, and WBC.
Use caution with concurrent NSAID use
and/or dehydration + high dose
vancomycin
secondary to risk of induced acute renal
failure
Pediatric Guidelines for IV Medication Administration
NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist.
Version 9/28/2008 Barb Maas Pharm. D.
24
Approved For
Drug
ICU
ED
Telemetry
Required
Acute
Care
IVP IV
Infusion
Concen
tration Usual Dosing and
Administration
Comments
Vasopressin X X X PTS <50 kg:
DI: 5 units/
500 mlsNS
SHOCK: 50
units/
250 mLs NS
PTS>50
kg/adults
DI: 10
units/250
mls NS
SH0CK:
40units/
100 mLNS
IVP: ACLS 40 units over 15-30 seconds
PTS <50 kg:
DI :0.0005 unit/kg/hr; double dose as needed every 30
mins to MAX 0.01 units/kg/hr
SHOCK:0.02-0.12 units/kg/hr up to 2.4 units total/hr
PTS>50 kg/adults:
DI :0.0005 unit/kg/hr; double dose as needed every 30
mins to MAX 0.01 units/kg/hr
Hypotension/Shock: 0.04-0.1 units/MINUTE
Central Vein Preferred. Monitor fluid
intake and output, urine specific gravity,
urine and serum osmolality, serum and
urine sodium.
Monitor BP, S/S ischemia( digital, gut,
coronary)
Vecuronium
(Norcuron®
)
HIGH RISK MED
X X X IVP: Dilute to
1 mg/mL
Continuous
Infusion:
50 mg/100 mL
D5W
IVP: Over seconds
Pedi Dosing: Neonates: 0.05-0.2mg/kg/dose IV q1=2 hrs
or per hr as continuous infusion.
Monitor assisted ventilator status, heart
rate, blood pressure, peripheral nerve
stimulator measuring twitch response.
Patients must be intubated and properly
sedated.
Verapamil (Isoptin®
,
Calan®
)
X X X X IVP: 1-2.5
mg/mL
Infusion:
50 mg/100 mL
D5W
IVP: Over 2-5 minutes
Children 1-16 years: 0.1-0.3 mg/kg/doseMAX initial
dose 5 mg, MR in 15-30 minutes x 1 with MAX of 0.3
mg/kg to 10 mg/dose
Not recommended in infants. Monitor
EKG, blood pressure and heart rate. IV
calcium should be readily available.
Voriconazole
(VFend®
)
X X X Diluted by
pharmacy to
0.5-5 mg/mL
Infusion: Over 1-2 hrs not to exceed 3 mg/kg/hr
Dose:3-6 mg/kg/dose q 12 hr, esophageal candidiasis
doses may be lower
Patients may commonly experience
reversible visual changes. Monitor
electrolytes. Use cautiously in patients
with proarrythmic conditions. Infectious
disease approval required. Do not use
IV form in renal failure
References
Lexi-Comp’s Pediatric Dosage Handbook- 14th
Edition
Pediatric Injectable Drugs-8th
Edition
2008 Intravenous Medications-24th
Edition
Micromedex
UMMMC Adult Guidelines for IV Medication Administration 2007
VUMC IV Medication Administration Chart revised 09/21/04
University of Kentucky Chandler Medical Center Pediatric IVP/Infusion Drug Lists 2005
Children’s Hospital and Clinics of Minnesotta Pediatric IV Administration Guidelines
Revised 09/05
Editor: Barbara Maas Pharm. D.
Primary Reviewers/Co-editors: Angela Gilchrist Pharm. D., Amy Hellinger Pharm. D.,
CharlesTurck Pharm. D.
Primary Nursing Reviewers: Carol Kronopolis, Charles Wheeler, Lynn D’Angelo,
Rosemary Cerquiera
Primary Physician Reviewers: Hospitalist- Tom Guggina ICU Attending- Scott Bateman
ER Attending-Mariann Manno
Appoved by Pharmacy and Therapeutics 09/14/08
Add for future: Cosyntropin, alteplase, lopressor, gancyclovir, immune globulin, sodium
chloride 3%, etomidate

More Related Content

Similar to pediatric-guidelines-for-medications.pdf

RINO DRUGS PPT.pptx
RINO DRUGS PPT.pptxRINO DRUGS PPT.pptx
RINO DRUGS PPT.pptxHemaBalan5
 
Emergency parenteral drugs_list_2009
Emergency parenteral drugs_list_2009Emergency parenteral drugs_list_2009
Emergency parenteral drugs_list_2009Lucky Khan
 
Anticonvulsants, anticoagulants
Anticonvulsants, anticoagulantsAnticonvulsants, anticoagulants
Anticonvulsants, anticoagulantsPriyanka Gohil
 
SBP (National Hepatic Institute)
SBP (National Hepatic Institute)SBP (National Hepatic Institute)
SBP (National Hepatic Institute)Mohamed Moustafa
 
Pals fluids and meds
Pals fluids and medsPals fluids and meds
Pals fluids and medsdjorgenmorris
 
Drug Dose.pdf
Drug Dose.pdfDrug Dose.pdf
Drug Dose.pdfandea6
 
Acetylcysteine Injection USP Taj Pharma SmPC
Acetylcysteine Injection USP Taj Pharma SmPCAcetylcysteine Injection USP Taj Pharma SmPC
Acetylcysteine Injection USP Taj Pharma SmPCTajPharmaQC
 
Medications in pediatrics
Medications in pediatricsMedications in pediatrics
Medications in pediatricsPratik Kumar
 
Medications in pediatrics
Medications in pediatricsMedications in pediatrics
Medications in pediatricsPratik Kumar
 
Pre-eclampsia
Pre-eclampsiaPre-eclampsia
Pre-eclampsiaEddie Lim
 
Hypertensive disorders in pregnancy recent guidelines fogsi 2014
Hypertensive disorders in pregnancy recent guidelines fogsi 2014Hypertensive disorders in pregnancy recent guidelines fogsi 2014
Hypertensive disorders in pregnancy recent guidelines fogsi 2014Dr Meenakshi Sharma
 
Antiarrhythmic drugs & Anaesthesia for Cardioversion
Antiarrhythmic drugs & Anaesthesia for CardioversionAntiarrhythmic drugs & Anaesthesia for Cardioversion
Antiarrhythmic drugs & Anaesthesia for Cardioversionleenatayshete
 
Hypertension disorders during pregnancy
Hypertension disorders during pregnancyHypertension disorders during pregnancy
Hypertension disorders during pregnancyVasundhara Hospital
 

Similar to pediatric-guidelines-for-medications.pdf (20)

RINO DRUGS PPT.pptx
RINO DRUGS PPT.pptxRINO DRUGS PPT.pptx
RINO DRUGS PPT.pptx
 
Emergency parenteral drugs_list_2009
Emergency parenteral drugs_list_2009Emergency parenteral drugs_list_2009
Emergency parenteral drugs_list_2009
 
Anticonvulsants, anticoagulants
Anticonvulsants, anticoagulantsAnticonvulsants, anticoagulants
Anticonvulsants, anticoagulants
 
SBP (National Hepatic Institute)
SBP (National Hepatic Institute)SBP (National Hepatic Institute)
SBP (National Hepatic Institute)
 
Pals fluids and meds
Pals fluids and medsPals fluids and meds
Pals fluids and meds
 
Drug Dose.pdf
Drug Dose.pdfDrug Dose.pdf
Drug Dose.pdf
 
Acls pharmacology
Acls pharmacologyAcls pharmacology
Acls pharmacology
 
Acetylcysteine Injection USP Taj Pharma SmPC
Acetylcysteine Injection USP Taj Pharma SmPCAcetylcysteine Injection USP Taj Pharma SmPC
Acetylcysteine Injection USP Taj Pharma SmPC
 
Medications in pediatrics
Medications in pediatricsMedications in pediatrics
Medications in pediatrics
 
Medications in pediatrics
Medications in pediatricsMedications in pediatrics
Medications in pediatrics
 
Emergency drugs
Emergency drugsEmergency drugs
Emergency drugs
 
Emergency drugs
Emergency drugsEmergency drugs
Emergency drugs
 
Magnesium sulfate
Magnesium sulfateMagnesium sulfate
Magnesium sulfate
 
Pre-eclampsia
Pre-eclampsiaPre-eclampsia
Pre-eclampsia
 
Magnesium sulfate
Magnesium sulfateMagnesium sulfate
Magnesium sulfate
 
Hypertensive disorders in pregnancy recent guidelines fogsi 2014
Hypertensive disorders in pregnancy recent guidelines fogsi 2014Hypertensive disorders in pregnancy recent guidelines fogsi 2014
Hypertensive disorders in pregnancy recent guidelines fogsi 2014
 
Eclampsia
EclampsiaEclampsia
Eclampsia
 
Sepsis Treatment
Sepsis TreatmentSepsis Treatment
Sepsis Treatment
 
Antiarrhythmic drugs & Anaesthesia for Cardioversion
Antiarrhythmic drugs & Anaesthesia for CardioversionAntiarrhythmic drugs & Anaesthesia for Cardioversion
Antiarrhythmic drugs & Anaesthesia for Cardioversion
 
Hypertension disorders during pregnancy
Hypertension disorders during pregnancyHypertension disorders during pregnancy
Hypertension disorders during pregnancy
 

More from MuhammadAbbasWali

1- Nursing_Status_and_Image.pptx
1- Nursing_Status_and_Image.pptx1- Nursing_Status_and_Image.pptx
1- Nursing_Status_and_Image.pptxMuhammadAbbasWali
 
Lect 3. Pakistan Health Care System.pdf
Lect 3. Pakistan Health Care  System.pdfLect 3. Pakistan Health Care  System.pdf
Lect 3. Pakistan Health Care System.pdfMuhammadAbbasWali
 
Assessment of the Breast, Axilla _ Genitalia, Educational Platform.pptx
Assessment of the Breast, Axilla _ Genitalia, Educational Platform.pptxAssessment of the Breast, Axilla _ Genitalia, Educational Platform.pptx
Assessment of the Breast, Axilla _ Genitalia, Educational Platform.pptxMuhammadAbbasWali
 
Anti-Neoplastic Drugs-1.pptx
Anti-Neoplastic Drugs-1.pptxAnti-Neoplastic Drugs-1.pptx
Anti-Neoplastic Drugs-1.pptxMuhammadAbbasWali
 
Adolescent reproductive and sexual health.pdf
Adolescent reproductive and sexual health.pdfAdolescent reproductive and sexual health.pdf
Adolescent reproductive and sexual health.pdfMuhammadAbbasWali
 
finalppt-131008044739-phpapp02.pdf
finalppt-131008044739-phpapp02.pdffinalppt-131008044739-phpapp02.pdf
finalppt-131008044739-phpapp02.pdfMuhammadAbbasWali
 
Autoimmune disorders, Educational Platform.pptx
Autoimmune disorders, Educational Platform.pptxAutoimmune disorders, Educational Platform.pptx
Autoimmune disorders, Educational Platform.pptxMuhammadAbbasWali
 
metabolism-120323035449-phpapp01.pdf
metabolism-120323035449-phpapp01.pdfmetabolism-120323035449-phpapp01.pdf
metabolism-120323035449-phpapp01.pdfMuhammadAbbasWali
 
Lecture 3 Cell_structure_function.ppt
Lecture 3 Cell_structure_function.pptLecture 3 Cell_structure_function.ppt
Lecture 3 Cell_structure_function.pptMuhammadAbbasWali
 
Lect-4. Weight Management unit-III .pdf
Lect-4. Weight Management unit-III .pdfLect-4. Weight Management unit-III .pdf
Lect-4. Weight Management unit-III .pdfMuhammadAbbasWali
 
UNIT 03 Final Adrenergic _ Anti Adrenergic Drugs, Educational Platform.pptx
UNIT 03 Final Adrenergic _ Anti Adrenergic Drugs, Educational Platform.pptxUNIT 03 Final Adrenergic _ Anti Adrenergic Drugs, Educational Platform.pptx
UNIT 03 Final Adrenergic _ Anti Adrenergic Drugs, Educational Platform.pptxMuhammadAbbasWali
 
Loss, Death, and Grieving.pptx 222222-1.pptx
Loss, Death, and Grieving.pptx 222222-1.pptxLoss, Death, and Grieving.pptx 222222-1.pptx
Loss, Death, and Grieving.pptx 222222-1.pptxMuhammadAbbasWali
 
Lecture 10 Lymphatic System.pptx
Lecture 10 Lymphatic System.pptxLecture 10 Lymphatic System.pptx
Lecture 10 Lymphatic System.pptxMuhammadAbbasWali
 

More from MuhammadAbbasWali (20)

1- Nursing_Status_and_Image.pptx
1- Nursing_Status_and_Image.pptx1- Nursing_Status_and_Image.pptx
1- Nursing_Status_and_Image.pptx
 
PHARMACOKINETICS BScN.pptx
PHARMACOKINETICS BScN.pptxPHARMACOKINETICS BScN.pptx
PHARMACOKINETICS BScN.pptx
 
Lect 3. Pakistan Health Care System.pdf
Lect 3. Pakistan Health Care  System.pdfLect 3. Pakistan Health Care  System.pdf
Lect 3. Pakistan Health Care System.pdf
 
Assessment of the Breast, Axilla _ Genitalia, Educational Platform.pptx
Assessment of the Breast, Axilla _ Genitalia, Educational Platform.pptxAssessment of the Breast, Axilla _ Genitalia, Educational Platform.pptx
Assessment of the Breast, Axilla _ Genitalia, Educational Platform.pptx
 
Anti-Neoplastic Drugs-1.pptx
Anti-Neoplastic Drugs-1.pptxAnti-Neoplastic Drugs-1.pptx
Anti-Neoplastic Drugs-1.pptx
 
Adolescent reproductive and sexual health.pdf
Adolescent reproductive and sexual health.pdfAdolescent reproductive and sexual health.pdf
Adolescent reproductive and sexual health.pdf
 
finalppt-131008044739-phpapp02.pdf
finalppt-131008044739-phpapp02.pdffinalppt-131008044739-phpapp02.pdf
finalppt-131008044739-phpapp02.pdf
 
Autoimmune disorders, Educational Platform.pptx
Autoimmune disorders, Educational Platform.pptxAutoimmune disorders, Educational Platform.pptx
Autoimmune disorders, Educational Platform.pptx
 
Lecture 1 22.07.2023.pptx
Lecture 1 22.07.2023.pptxLecture 1 22.07.2023.pptx
Lecture 1 22.07.2023.pptx
 
Unit 1 A&P.ppt
Unit 1 A&P.pptUnit 1 A&P.ppt
Unit 1 A&P.ppt
 
metabolism-120323035449-phpapp01.pdf
metabolism-120323035449-phpapp01.pdfmetabolism-120323035449-phpapp01.pdf
metabolism-120323035449-phpapp01.pdf
 
Lecture 3 Cell_structure_function.ppt
Lecture 3 Cell_structure_function.pptLecture 3 Cell_structure_function.ppt
Lecture 3 Cell_structure_function.ppt
 
Lecture 9 CVS.pptx
Lecture 9 CVS.pptxLecture 9 CVS.pptx
Lecture 9 CVS.pptx
 
Lecture 9 CVS.pptx
Lecture 9 CVS.pptxLecture 9 CVS.pptx
Lecture 9 CVS.pptx
 
Lect-4. Weight Management unit-III .pdf
Lect-4. Weight Management unit-III .pdfLect-4. Weight Management unit-III .pdf
Lect-4. Weight Management unit-III .pdf
 
UNIT 03 Final Adrenergic _ Anti Adrenergic Drugs, Educational Platform.pptx
UNIT 03 Final Adrenergic _ Anti Adrenergic Drugs, Educational Platform.pptxUNIT 03 Final Adrenergic _ Anti Adrenergic Drugs, Educational Platform.pptx
UNIT 03 Final Adrenergic _ Anti Adrenergic Drugs, Educational Platform.pptx
 
Loss, Death, and Grieving.pptx 222222-1.pptx
Loss, Death, and Grieving.pptx 222222-1.pptxLoss, Death, and Grieving.pptx 222222-1.pptx
Loss, Death, and Grieving.pptx 222222-1.pptx
 
environment.pptx
environment.pptxenvironment.pptx
environment.pptx
 
Lecture 10 Lymphatic System.pptx
Lecture 10 Lymphatic System.pptxLecture 10 Lymphatic System.pptx
Lecture 10 Lymphatic System.pptx
 
oxygenation.pptx
oxygenation.pptxoxygenation.pptx
oxygenation.pptx
 

Recently uploaded

Measures of Position DECILES for ungrouped data
Measures of Position DECILES for ungrouped dataMeasures of Position DECILES for ungrouped data
Measures of Position DECILES for ungrouped dataBabyAnnMotar
 
ClimART Action | eTwinning Project
ClimART Action    |    eTwinning ProjectClimART Action    |    eTwinning Project
ClimART Action | eTwinning Projectjordimapav
 
Keynote by Prof. Wurzer at Nordex about IP-design
Keynote by Prof. Wurzer at Nordex about IP-designKeynote by Prof. Wurzer at Nordex about IP-design
Keynote by Prof. Wurzer at Nordex about IP-designMIPLM
 
ANG SEKTOR NG agrikultura.pptx QUARTER 4
ANG SEKTOR NG agrikultura.pptx QUARTER 4ANG SEKTOR NG agrikultura.pptx QUARTER 4
ANG SEKTOR NG agrikultura.pptx QUARTER 4MiaBumagat1
 
The Contemporary World: The Globalization of World Politics
The Contemporary World: The Globalization of World PoliticsThe Contemporary World: The Globalization of World Politics
The Contemporary World: The Globalization of World PoliticsRommel Regala
 
Integumentary System SMP B. Pharm Sem I.ppt
Integumentary System SMP B. Pharm Sem I.pptIntegumentary System SMP B. Pharm Sem I.ppt
Integumentary System SMP B. Pharm Sem I.pptshraddhaparab530
 
Concurrency Control in Database Management system
Concurrency Control in Database Management systemConcurrency Control in Database Management system
Concurrency Control in Database Management systemChristalin Nelson
 
Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)
Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)
Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)lakshayb543
 
Dust Of Snow By Robert Frost Class-X English CBSE
Dust Of Snow By Robert Frost Class-X English CBSEDust Of Snow By Robert Frost Class-X English CBSE
Dust Of Snow By Robert Frost Class-X English CBSEaurabinda banchhor
 
GRADE 4 - SUMMATIVE TEST QUARTER 4 ALL SUBJECTS
GRADE 4 - SUMMATIVE TEST QUARTER 4 ALL SUBJECTSGRADE 4 - SUMMATIVE TEST QUARTER 4 ALL SUBJECTS
GRADE 4 - SUMMATIVE TEST QUARTER 4 ALL SUBJECTSJoshuaGantuangco2
 
How to do quick user assign in kanban in Odoo 17 ERP
How to do quick user assign in kanban in Odoo 17 ERPHow to do quick user assign in kanban in Odoo 17 ERP
How to do quick user assign in kanban in Odoo 17 ERPCeline George
 
How to Add Barcode on PDF Report in Odoo 17
How to Add Barcode on PDF Report in Odoo 17How to Add Barcode on PDF Report in Odoo 17
How to Add Barcode on PDF Report in Odoo 17Celine George
 
Oppenheimer Film Discussion for Philosophy and Film
Oppenheimer Film Discussion for Philosophy and FilmOppenheimer Film Discussion for Philosophy and Film
Oppenheimer Film Discussion for Philosophy and FilmStan Meyer
 
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17Celine George
 
THEORIES OF ORGANIZATION-PUBLIC ADMINISTRATION
THEORIES OF ORGANIZATION-PUBLIC ADMINISTRATIONTHEORIES OF ORGANIZATION-PUBLIC ADMINISTRATION
THEORIES OF ORGANIZATION-PUBLIC ADMINISTRATIONHumphrey A Beña
 
INTRODUCTION TO CATHOLIC CHRISTOLOGY.pptx
INTRODUCTION TO CATHOLIC CHRISTOLOGY.pptxINTRODUCTION TO CATHOLIC CHRISTOLOGY.pptx
INTRODUCTION TO CATHOLIC CHRISTOLOGY.pptxHumphrey A Beña
 
Field Attribute Index Feature in Odoo 17
Field Attribute Index Feature in Odoo 17Field Attribute Index Feature in Odoo 17
Field Attribute Index Feature in Odoo 17Celine George
 
Inclusivity Essentials_ Creating Accessible Websites for Nonprofits .pdf
Inclusivity Essentials_ Creating Accessible Websites for Nonprofits .pdfInclusivity Essentials_ Creating Accessible Websites for Nonprofits .pdf
Inclusivity Essentials_ Creating Accessible Websites for Nonprofits .pdfTechSoup
 

Recently uploaded (20)

Measures of Position DECILES for ungrouped data
Measures of Position DECILES for ungrouped dataMeasures of Position DECILES for ungrouped data
Measures of Position DECILES for ungrouped data
 
ClimART Action | eTwinning Project
ClimART Action    |    eTwinning ProjectClimART Action    |    eTwinning Project
ClimART Action | eTwinning Project
 
Keynote by Prof. Wurzer at Nordex about IP-design
Keynote by Prof. Wurzer at Nordex about IP-designKeynote by Prof. Wurzer at Nordex about IP-design
Keynote by Prof. Wurzer at Nordex about IP-design
 
ANG SEKTOR NG agrikultura.pptx QUARTER 4
ANG SEKTOR NG agrikultura.pptx QUARTER 4ANG SEKTOR NG agrikultura.pptx QUARTER 4
ANG SEKTOR NG agrikultura.pptx QUARTER 4
 
The Contemporary World: The Globalization of World Politics
The Contemporary World: The Globalization of World PoliticsThe Contemporary World: The Globalization of World Politics
The Contemporary World: The Globalization of World Politics
 
Integumentary System SMP B. Pharm Sem I.ppt
Integumentary System SMP B. Pharm Sem I.pptIntegumentary System SMP B. Pharm Sem I.ppt
Integumentary System SMP B. Pharm Sem I.ppt
 
Concurrency Control in Database Management system
Concurrency Control in Database Management systemConcurrency Control in Database Management system
Concurrency Control in Database Management system
 
Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)
Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)
Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)
 
Dust Of Snow By Robert Frost Class-X English CBSE
Dust Of Snow By Robert Frost Class-X English CBSEDust Of Snow By Robert Frost Class-X English CBSE
Dust Of Snow By Robert Frost Class-X English CBSE
 
GRADE 4 - SUMMATIVE TEST QUARTER 4 ALL SUBJECTS
GRADE 4 - SUMMATIVE TEST QUARTER 4 ALL SUBJECTSGRADE 4 - SUMMATIVE TEST QUARTER 4 ALL SUBJECTS
GRADE 4 - SUMMATIVE TEST QUARTER 4 ALL SUBJECTS
 
YOUVE GOT EMAIL_FINALS_EL_DORADO_2024.pptx
YOUVE GOT EMAIL_FINALS_EL_DORADO_2024.pptxYOUVE GOT EMAIL_FINALS_EL_DORADO_2024.pptx
YOUVE GOT EMAIL_FINALS_EL_DORADO_2024.pptx
 
How to do quick user assign in kanban in Odoo 17 ERP
How to do quick user assign in kanban in Odoo 17 ERPHow to do quick user assign in kanban in Odoo 17 ERP
How to do quick user assign in kanban in Odoo 17 ERP
 
How to Add Barcode on PDF Report in Odoo 17
How to Add Barcode on PDF Report in Odoo 17How to Add Barcode on PDF Report in Odoo 17
How to Add Barcode on PDF Report in Odoo 17
 
Oppenheimer Film Discussion for Philosophy and Film
Oppenheimer Film Discussion for Philosophy and FilmOppenheimer Film Discussion for Philosophy and Film
Oppenheimer Film Discussion for Philosophy and Film
 
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17
 
THEORIES OF ORGANIZATION-PUBLIC ADMINISTRATION
THEORIES OF ORGANIZATION-PUBLIC ADMINISTRATIONTHEORIES OF ORGANIZATION-PUBLIC ADMINISTRATION
THEORIES OF ORGANIZATION-PUBLIC ADMINISTRATION
 
INTRODUCTION TO CATHOLIC CHRISTOLOGY.pptx
INTRODUCTION TO CATHOLIC CHRISTOLOGY.pptxINTRODUCTION TO CATHOLIC CHRISTOLOGY.pptx
INTRODUCTION TO CATHOLIC CHRISTOLOGY.pptx
 
Field Attribute Index Feature in Odoo 17
Field Attribute Index Feature in Odoo 17Field Attribute Index Feature in Odoo 17
Field Attribute Index Feature in Odoo 17
 
Inclusivity Essentials_ Creating Accessible Websites for Nonprofits .pdf
Inclusivity Essentials_ Creating Accessible Websites for Nonprofits .pdfInclusivity Essentials_ Creating Accessible Websites for Nonprofits .pdf
Inclusivity Essentials_ Creating Accessible Websites for Nonprofits .pdf
 
FINALS_OF_LEFT_ON_C'N_EL_DORADO_2024.pptx
FINALS_OF_LEFT_ON_C'N_EL_DORADO_2024.pptxFINALS_OF_LEFT_ON_C'N_EL_DORADO_2024.pptx
FINALS_OF_LEFT_ON_C'N_EL_DORADO_2024.pptx
 

pediatric-guidelines-for-medications.pdf

  • 1. Pediatric Guidelines for IV Medication Administration NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist. Version 9/28/2008 Barb Maas Pharm. D. 1 Approved For Drug ICU ED Telemetry Required Acute Care IVP IV Infusion Concent- ration Usual Dosing and Administration Comments Acetazolamide (Diamox® ) X X X Dilute to MAX of 100 mg/mL 5-10 mg/kg/dose MR q 8 or 6 hrs. MAX dose: 25 mg/kg/dose up to 500 mg/dose MAX Rate: IVP over 1 minute. Monitor serum electrolytes Acetylcysteine (Acetadote®) X Bolus + infusion X Infusion only X 30 gm/1000 mL (30 mg/mL) Requires toxicology approval. Bolus: 150mg/kg over 1 hr. Maintenance: 15-7.5mg/kg/hr. See dosing protocol or contact pharmacy for weight-based protocol. When used in acetaminophen overdose, monitor serum acetaminophen concentrations; monitor LFTs. Bolus doses, monitor for hypotension, flushing, anaphylaxis Bolus doses must be completed in critical care areas only. Maintenance IV infusions may be continued or initiated in acute care areas. Acyclovir X X X Diluted to <5 mg/mL Infusion over 60-90 minutes. Dose: 5-20 mg/kg/dose q 8hrs. Patient should be well hydrated to prevent nephrotoxicity. Monitor urine output, Scr. Adenosine (Adenocard® ) X X X See restriction . X 6 mg/2 mL. (3mg/ml) DOSE:0.05-0.1 mg/kg up to 6 mg over 1-2 seconds followed by rapid NS flush. May increase dose by 0.1- 0.2 mg/kg q2 minutes up to 12 mg/dose every 1-2 mins till termination of arrhythmia to a MAX CUM dose of 0.3 mg/kg/dose upto 30 mg. > 50kg: 6mg, 12mg, 12mg Restriction: In acute care areas, doses must be administered by a physician. . Communication with the ICU team prior to adenosine administration is required. An attending Hospitalist, Cardiologist, or ICU physician must be at the bedside. A continuous ECG rhythm strip must be obtained during dosing to monitor and document drug effects Albumin 5% (forhypovolemia, hypoalbuminemia X X X 5% (50 mg/mL) 0.5-1 gm/kg/dose (10-20 mLs/kg/dose). Infusion over 30- 60 minutes. In emergencies, may administer over 15 minutes. Adult MAX: 600mls/hr Rapid infusion may cause hypertension and pulmonary edema. Monitor vital signs and fluid balance. Use within 4 hours of opening vial. 60 micron filter/tubing supplied by pharmacy Albumin 25% (forhypoproteinemia w/ generalized edema) X X X 25% (250 mg/mL) 0.25-1 gm/kg/dose (1-4 ms/kg/dose) Infusion as tolerated over 30-120 minutes. Adult MAX :180ml/hr Rapid infusion may cause hypertension & pulmonary edema. Monitor vital signs and fluid balance. Use within 4 hrs of opening. 60 micron filter/tubing supplied by pharmacy Alprostadil, PGE1 Prostin VR Pediatric®) X X X Contin- uous infusion Dilute 500 mcg in 50mls NS (10 mcg/ml) Initial: 0.05- 0.1 mcg/kg/min. Range: 0.01 up to MAX 0.4mcg/kg/minute Infuse via large vein. Monitor arterial pressure, RR, HR, oxygen saturation, temp. Amikacin (Amikin®) X X X Diluted to < 5 mg/mL 5-10mg/kg/dose q8hrs with NL renal function. Infusion: Over 30 minutes. Urine output, Serum creatinine, Peak and trough concentrations.
  • 2. Pediatric Guidelines for IV Medication Administration NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist. Version 9/28/2008 Barb Maas Pharm. D. 2 Approved For DrugDrD ICU ED Telemetry Required Acute Care IVP IV Infusion Concen- tration Usual Dosing and Administration Comments Amiodarone (Cordarone®) X X X Bolus in code only No infusion X X Bolus diluted to 1.5-3 mg/mLin D5W Infusion 450 mg/ 250 mL in D5W BOLUS: PALS for pulseless VF/VT5 mg/kg (MAX 300 mg/dose) given over 5-10 minutes. - 0.22 micron filter preferred . Flush post dose. For perfusing VF/VT 5 mg/kg over 20-60 min, MR X 3 Infusion: Initial dose of 5 mcg/kg/min, increase to desired effect to a MAX of 15 mcg/kg/min Central line preferred for concentrations exceeding 2 mg/mL. Dedicated filtered (0.22 micron) line required. Continuous BP/cardiac monitoring, thyroid function, LFTs, and pulmonary function should be monitored frequently. Ampicillin X X X slow X Dilute to <20 mg/mL IVP: not to exceed 10 mg/kg/minute. Infusion: over 15-30 minutes Dosing: 100-400 mg/kg/day divided every 6 hrs. MAX 12 gm/day Adjust with renal dysfunction. Ampicillin/ Sulbactam (Unasyn®) X X X slow X Dilute to <30 mg/mL =(amp 20 mg/ sulb 10 mg) IVP: not to exceed 15 mg/kg/minute (amp/sulb) Infusion: Over 15-30 minutes >1 month: 150-225 mg/kg/day (amp/sulb) divided every 6 hrs Children: 150-300 mg/kg/day (amp/sulb) divided every 6 hrs. (non-meningitic doses) (MAX dose: 12 gm ampisulb/day) Unsayn: Each 1.5mg unasyn=1mg apicillin +0.5mg sulbactam. With prolonged therapy, monitor hematologic, renal and hepatic function. Observe for change in bowel frequency. Atropine X X X MD available X 0.1 mg/mL; 1 mg/mL IV Push: given over 1 minute Dosing: 0.01-0.2 mg/kg (MIN 0.1 mg) Child: up to 0.5 mg, MRx1 Adolescent: up to 1 mg, MRx 1 Please see reference for dosing for specific indications. Monitor vital signs and EKG; monitor for side effects including dry mouth, dizziness and palpitations. Azithromycin (Zithromax®) X X X Dilute to 2 mg/mL Infusion:MAX concentration of 2 mg/mL over 1 hr Dosing: 5-10 mg/kg/day as q 24 h (MAX 500 mg) Single dose regimen: 30mg/kg X 1 (MAX 1500mg) For specific indications, please consult pedi reference for recommendations. Monitor for pain at infusion site, LFTs, WBC and infection. Aztreonam (Azactam®) X X X X Dilute to < 20 mg/mL IVP: over 3-5 min Infusion: Over 20 minutes Dosing: >1 month-90-120 mg/kg/day div q 8h or q 6 h. CF: 50 mg/kg/dose q 6 hrs MAX 8 gm/day Adjust dosing with renal dysfunction.
  • 3. Pediatric Guidelines for IV Medication Administration NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist. Version 9/28/2008 Barb Maas Pharm. D. 3 Approved For Drug ICU ED Telemetry Required Acute Care IVP IV Infusion Concen- tration Usual Dosing and Administration Comments Bumetanide (Bumex®) X X X X 0.25 mg/mL Dosing:0.015-0.1 mg/kg/dose up to 4 mg q 6-24 hrs (MAX dose is 10 mg/day, 20 mg/day w/ RF)) IV Push: over 1-2 minutes MAX 1mg/min Monitor blood pressure, serum electrolytes and renal function. Caffeine Citrate (Cafcit) For apnea X X X 20 mg/mL citrate salt (=10 mg/mL caffeine base) Loading: 10-20 mg/kg citrate salt infused over 30 minutes Maintenance: 5 mg/kg/day as citrate salt once daily starting 24 hours after bolus doseinfused over ≥ 10 minutes Clarify if dosing is as citrate salt or caffeine base. Must be specified on medication order. May dilute in D5W Monitor heart rate, number and severity of apnea spells, and serum caffeine levels Caffeine sodium benzoate For spinal headache X X X Dilute to 0.5 mg/mL Adults: 500 mgs as a single dosediluted with 1000 mL NS and infused over 1 hour, followed by 1000 mL NS over 1 hour. Not to be administered in neonates(benzoates). Monitor heart rate. Calcium Chloride X Slow IVP X IVP In code only w/MD present. No infusion. X Slow IVP X 1 gm/ 10 mL vial Recommend use only in symptomatic hypocalcemia Bolus: 10-20 mg/kg/dose up to 1gm over a minimum of 10 minutes. Infusion: Do not exceed 45-90 mg/kg given over 1 hour Central Line preferred unless emergency administration. Do not administer I.M. or S.C. or use scalp, small hand or foot veins for IV administration since severe necrosis may occur. Monitor serum calcium (ionized calcium is recommended), heart rate and EKG. Do not infuse calcium chloride in same IV line as phosphate-containing solutions. Calcium Gluconate X Slow IVP X Slow IVP only. Slow IVP in code w/ MD present. Infusion OK X Slow IVP X 1 gm/50 mL =20 mg/mL 200-500 mg/kg/DAY as continuous infusion or in 4 divided doses Acute::Usual 100mg/kg or 1gm MAX 3gm over 10 minutes Non-Acute: Usual 50-100mg/kg not to exceed 2gm over no less than 60 minutes. MAX: 200mg/kg up to 3gm Do not infuse calcium gluconate in same IV line as phosphate-containing solutions. Monitor serum calcium (ionized calcium is recommended), heart rate and EKG. See label comments on Pedi IV Calcium Gluconate Bags Cefazolin (Kefzol) X X X X Dilute to < 20mg/ml IVP: Over 3-5 minutes Infusion: Over 10-15 minutes Dosing:Neonates>2 kg, + 7 days-60 mg/kg/day div q 8h. Infants/Children: 50-100 mg/kg/day div q 8h Adolescent/Adult: 1-2 gm IV q 8h MAX ADULT DOSE: 12 gm/day Adjust dosing with renal dysfunction.
  • 4. Pediatric Guidelines for IV Medication Administration NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist. Version 9/28/2008 Barb Maas Pharm. D. 4 Approved For Drug ICU ED Telemetry Required Acute Care IVP IV Infusion Concen- tration Usual Dosing and Administration Comments Cefepime (Maxipime) X X X X Dilute to < 20 mg/mL IVP over 5 minutes. Infusion over 30 minutes Dosing 2 mo-16yo: 100-150 mg/kg/day div q 12 or 8 hrs. CF 50 mg/kg/dose q 8hr MAX 6 gm/day ID approval required for patients outside the ICU. Pseudomonal infections should be dosed at the higher end of the dosing range. Adjust dosing with renal dysfunction. Cefotaxime (Claforan®) X X X X Dilute to < 40 mg/mL IVP over 3-5 minutes Infusion: Over 10-30 minutes <7 days:+>2000 g:100-150 mg/kg/day div every 8-12 hrs > 7 days: >2000 g: 150-200 mg/kg/day divided every 6-8 hrs 1 month- 12 years: <50 kg: 100-200 mg/kg/day divided every 6-8 hoursMeningitis: 200-300 mg/kg/day divided every 4 or 6 hours (MAX 12 gm/day) > 50 kg: Moderate infection 1-2 gms q 6-8hrs, Severe 2 gms every 4 to6 hrs (MAX 12 g/day) Indicated in neonate < 2 weeks or in infants with clinically relevant hyperbilirubinemia who may be at risk for kernicturus. With prolonged therapy, monitor renal, hepatic, and hematologic function periodically; number and type of stools/day for diarrhea. Adjust dosing with renal dysfunction. Cefoxitin (Mefoxin®) X X X X Dilute to < 40mg/ml IVP over 5 minutes Infusion over 10-30 minutes Adjust dosing with renal dysfunction. Monitor INR with prolonged use Ceftazidime (Fortaz) X X X X Dilute to <40 mg/mL IVP over 3-5 minutes Infusion over 20-60 minutes < 7days >2 kg: 100-150 mg/kg/day div q 8-12 hrs >7 days >2 kg: 150 mg/kg/day div q 8h Infant/child: 100-150 mg/kg/day div q 8h CF: 150-300 mg/kg/day usual MAX 12 gm/day CO2 is produced with reconstitution. Remove pressure/air by venting vial prior to drawing up dose— Adjust dosing with renal dysfunction.. Ceftriaxone (Rocephin®) X X X X Dilute to < 20 mg/mL IVP over 5 minutes Infusion over 10-30 minutes Infants and Children: 50-75 mg/kg/day divided every 12- 24 hours Meningitis: 80-100 mg/kg/day divided every 12-24 hrs (MAX: 4 gm/day) *Do not use in any child <5kg, unless short-term IV access is unavailable. Avoid concurrent use in all patients requiring IV calcium supplementation. Monitor CBC, platelet count, renal and hepatic function tests periodically, number and type of stools/day for diarrhea. Chlorothiazide (Diuril®) X X X X 500 mg vial diluted with 18 mL SWI for a final concentration of 27.8 mg/mL IVPover 3-5 Infusionover 30 minutes in dextrose or NS <6 months: 2-8 mg/kg/day in 2 divided doses up to 20 mg/kg/day >6 months: 4 mg/kg/day in 1-2 divided doses up to 20 mg/kg/day. Do not administer I.M. or S.C. since extremely irritating to tissues. May be further diluted. Monitor serum electrolytes and blood pressure.
  • 5. Pediatric Guidelines for IV Medication Administration NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist. Version 9/28/2008 Barb Maas Pharm. D. 5 Approved For Drug ICU ED Telemetry Required Acute Care IVP IV Infusion Concen- tration Usual Dosing and Administration Comments Ciprofloxacin (Cipro®) X X X Dilute to < 2 mg/mL Infusion over 60 minutes Children 20-30 mg/kg/day divided q 12 h CF: 30 mg/kg/day divided q 8 or 12 hrs May cause venous irritation Cisatricurium (Nimbex®) HIGH RISK MED X X X 40 mg/100 mL 200mg/500ml MAX: 200 mg/100 mL Bolus:IVP: 0.1-0.2mg/kg over 5-10 seconds Infusion: 1-4 mcg/kg/minMAX 10 mcg/kg/min Monitor muscle twitch response to peripheral nerve stimulation, heart rate and blood pressure Not renally orhepatically metabolized Clindamycin (Cleocin®) X X X Dilute to < 18 mg/mL Infusion over 10-30 minutes, not to exceed 0.5 mg/kg/minute Dose: 20-40 mg/kg/day divided q 6 or 8 hrs Usual adult 600-900 mg IV q 8h MAX 4.8 gm/day Cyclosporine (Sandimmune®) X X X Dilute in D5W to < 2.5 mg/mL Initial: 5-6 mg/kg/dose (1/3 of oral dose) administered 4-12 hours prior to transplant Maintenance: 2-10 mg/kg/day in 2 divided doses. May be administered over 2-6 hours or as a continuous infusion. Doses prepared in glass. Use Non PVC tubing( ie// nitro tubing) Patients should be monitored continuously for ≥ the first 30 minutes of the infusion for signs of anaphylaxis. Monitor serum drug levels, serum creatinine and BP D10W X X X X 100 mg/mL Neonates: 100-200 mg/kg /dose (=1-2 mLs/kg) over 1 minute. Monitor blood and urine sugar, serum electrolytes and I & O. D25W X X X X 250 mg/ML 2.5GM/10ML SYRINGE Bolus: MAX of 200 mg/kg (=0.8 mLs/kg) over 1 minute not to exceed 6 mLs/minute if undiluted Infants <6 month: 0.25-0.5 gm/kg/dose (=1-2 mLs/kg) MAX of 25 g(50 mLs/dose) Infants >6 months-40 kg: 0.5-1 g/kg/dose (=2-4 mLs/kg); MAX of 25 g(50 mLs)/dose Hyperkalemia<40kg D25W-2mls/kg(0.5gm/kg) over 15-30 minutes + insulin regular 0.1unit/kg IV (MAX 50ml (=25gm) +5 units insulin/dose. For peripheral venous administration, dilute dextrose to MAX concentration of 12.5%. (1:1 with NS)preferred. Monitor blood and urine sugar, serum electrolytes and I & O. D50W X X X 500 mg/mL 25gm/50ml syringe Bolus: >40 kg not to exceed 3 mls/minute if undiluted Adolscent/Adult: 25-50 gms (50-100 mLs) over 5-30 minutes Hyperkalemia:adolescent/adult 25-50 gm + 5-10 units insulin (5gm (10ml) per 1 unit insulin) over 5-60 minutes. Avoid in infants/ young children. Dextrose 10-25% preferred. Peripheral: Dilution to 12.5% (1:3 D50:NS) preferred.
  • 6. Pediatric Guidelines for IV Medication Administration NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist. Version 9/28/2008 Barb Maas Pharm. D. 6 Approved For Drug ICU ED Telemetry Required Acute Care IV P IV Infusion Concen- ration Usual Dosing and Administration Comments Dexamethasone (Decadron) X X X 4 mg/mL Please see reference for dosing for specific indications (usual range 0.3-2 mg/kg/day as a generally up to 40 mg/day) divided q 6-24 hrs. If dose <10 mg, administer IV push over 1-4 minutes. If dose >10 mg, dilute with D5W or NS and infuse over 15- 30 mins Monitor hemoglobin, occult blood loss, serum potassium and glucose. Dexmedetomidine (Precedex) X X X Moderate sedation service + moderate sedation RN X 200 mcg/50 mL (4mcg/ml) Requires pediatric ICU, moderate sedation service, or anesthesiology attending approval Bolus( attending present) 0.5-1 mcg/kg over 10 minutes Infusion: Usual 0.2-0.7 mcg/kg/hr. Higher doses have been used. Ensure airway and respiratory support measures in place, monitor level of sedation, heart rate, respiration, rhythm. Bolus doses associated with bradycardia and hypotension. Diazepam (Valium) X X X X 5 mg/mL IVP: Peds< 40 kg not to exceed 1-2 mg/min, >40 kg 5 mg/min Dose:0.04-0.3 mg/kg/dose (up to 10 mg/dose) every 2-4 hours to MAX of 0.6 mg/kg within an 8-hour period if needed. May cause phlebitis Monitor heart rate, respiratory rate, blood pressure and mental status Digoxin (Lanoxin) X MD adminis- tration for loading doses only. X Maint- enance doses X Dilute to < 100 mcg/mL w/NS Infusion:Slowly administer over 5-10 mins Dosing: See age specific references Loading Dose: range 10-30 mg/kg divided in 3 doses over 16-24 hrs (as 50%/25%/25%) not to exceed total 1 mg dose. Maintenance: approx 1/3 of loading dose divided q 12 or 24 hrs. Rarely exceeds 10 mcg/kg/day up to 0.25 mg/day. c Loading dose requires telemetry. Not for maintenance dose. Monitor heart rate, rhythm, periodic EKGs, serum electrolytes, renal function and serum levels. Digoxin Immune Fab (DigiFAB) X X X X Dilute to 1-10 mg/mL with NS Requires toxicology consult! Dosing based on amount of digoxin ingested. Each 40mg vial binds 0.5mg digoxin IVP: If in Cardiac Arrest over3-5 minutes using. Infusion preferred. Infusion:Over 15-30 minutes through 0.22 micron filter. Decrease rate or hold if infusion reaction occurs. 0.22 micron filter required Monitor EKG, serum potassium and digoxin serum levels. Check for S/S of an acute allergic reaction. Diltiazem (Cardizem) X X X X 5 mg/mL for IVP Infusion 1 mg/mL Bolus: 0.25 mg/kg over 2- 5 minutes; if inadequate response, 0.35 mg/kg dose may be administered after 15 minutes Infusioncontinuous(start after IV bolus doses) < 50 kg (limited data) 0.05-0.15 mg/kg/hr up to 15 mg/hr Adult: 5-15 mg/hr During administration monitor EKG, heart rate, blood pressure and renal function. Diphenhydramine (Benadryl) X X X Dilute to <50 mg/mL IVP:0.5 mg/kg/min up to 25 mg/minute Infusion: Over 10-15 minutes Dosing: 0.5-2 mkg/dose(MAX 100 mg) up to 5 mg/kg/day(MAX 300 mg) divided q 6 hrs Monitor symptom relief and sedation
  • 7. Pediatric Guidelines for IV Medication Administration NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist. Version 9/28/2008 Barb Maas Pharm. D. 7 Approved For Drug ICU ED Telemetry Required Acute Care IV P IV Infusion Concen- tration Usual Dosing and Administration Comments Dobutamine X X X <10 kg 250 mg /250 mls > 10kg500 mg /250 mls MAX: 1000 mg/250 mL Infusion: continuous at 2-20 mcg/kg/minute. MAX 30 mcg/kg/min Monitor EKG, blood pressure, heart rate, CVP, MAP and urine output. Dopamine X X X <10 kg 200 mg /250 mL >10kg 400 mg /250 mL MAX: 800 mg/ 250 mL Infusion: continuous at 1-20 mcg/kg/min; titrate to desired response; MAX dose 30 mcg/kg/min. Central line preferred. Monitor EKG, blood pressure, heart rate, CVP, MAP and urine output. Doxycycline (Vibramycin) X X X Dilute to <=1 mg/mL Infusion: Doses < 100 mg over 1-2 hrs Children: (rarely used) 2-5 mg/kg/day divided q 12 or q 24 hrs not to exceed 100 mg/dose Adolescents/Adults:Rarely exceeds 200 mg/day. May cause phlebitis, dizziness, N/V Droperidol (Inapsine) X X In pts w/ cardiac history X X 2.5 mg/mL MAX: 2.5 mg/mL IVP: Slowly over 2-5 minutes Postop nausea/vomiting prophylaxis 0.05-0.06 mg/kg/dose; MAX 0.1 mg/kg up to 2.5 mg Postop nausea/vomiting treatment: 0.01-0.03 mg/kg/dose; MAX 0.1 mg/kg up to 2.5 mg Adult: 0.625-2.5 mg/dose Monitor blood pressure, heart rate, respiratory rate, temperature, serum potassium and magnesium. Observe for dystonias and extrapyramadial side effects. EKG monitoring is recommended in patients with a history of QT prolongation or cardiac disease. Enalaprilat (Vasotec) X X X MD available X < 1.25 mg/mL I5-10 mcg/kg/dose administered every 8-24 hours (as determined by blood pressure readings) over 5-15 minutes. MAX: 60 mcg/kg/day, rarely to exceed 20 mg/day Clinical response seen within 15 minutes, peak within 4 hrs. Monitor blood pressure, renal function, WBC, serum potassium and serum glucose. Enoxaparin (Lovenox) X X S C SC 100 mg/mL For doses <10 mg, a special dilution of 20mg/ml will be prepared by pharmacy Infants <2 months: Prophylaxis: 0.75 mg/kg every 12 hrs Treatment: 1.5 mg/kg every 12 hours Infants >2 months and <18 years: Prophylaxis: 0.5 mg/kg every 12 hours Treatment: 1 mg/kg every 12 hours Deep SC administration preferred(not im) and allowed in all nursing units. Do not rub injection site after administration. Monitor CBC, platelets, stool occult blood tests. If antifactorXa level are indicated, draw peak levels 4 hrs post dose.
  • 8. Pediatric Guidelines for IV Medication Administration NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist. Version 9/28/2008 Barb Maas Pharm. D. 8 Approved For Drug ICU ED Telemetry Required Acute Care IV P IV Infusion Concen tration Usual Dosing and Administration Comments Epinephrine (Adrenalin® ) X X X SC, IVP For anaphy- laxis, CPR X X For IVP 1:10,000  (0.1 mg/mL) For ET/ SC /Drips 1:1,000 (1 mg/mL) Drip Concentrations < 10 kg 8mg / 250mls 10-50kg 16 mg/ 250mls >50 kg 4 mg/ 250 mls MAX: 16 mg/250 mL- IV Push: 0.01 mg/kg (=0.1 mL/kg) up to 1 mg (10 mLs) over 1 minute, every 3-5 minsprn. Infusion: 0.1-1 mcg/kg/min; titrate dose to desired effect. Central line preferred. Do not use if pink in color. Monitor EKG, heart rate, blood pressure, pulmonary function and injection site monitoring for extravasation. Ertapenem (Invanz® ) X X X Dilute to < 20 mg/mL in NS only. Infusion: Over 30 minutes. 3 mths-12yrs: 15 mg/kg/dose q 12 h up to 1 gm/24 hrs Adolescent/Adult: 1 gm q 24 hrs. Do not infuse with dextrose containing solutions. Erythropoetin (EPO® , Procrit® ) X X X Various, may be given undiluted or diluted 1:1 with NS IVPush:Over no less than 1 minute, SC preferred, See pediatric dosing recommendations for disease specific guidelines. Range 10-600units/kg Do not shake vial. Monitor Hgb/Hct, Iron stores, BP Esmolol (Brevibloc® ) X X X X <10 mg/mLfor IVP 20 mg/mL drip Bolus: 250-500 mcg/kg over 1-2 minutes Infusion: 50-300 mcg/kg/min; titrate up every 20 mins to desired effect. Dosing may be higher with SVT (up to 1000 mcg/kg/min in small children) EKG, BP, HR, respiratory rate monitoring mandatory during administration. Esomeprazole (Nexium® ) X X X X < 4mg/ml 1-2 mg/kg/day administered in 1-2 divided doses. Usual adult dose 20-40 mg/day MAX 80 mg IVP: Dilute with 5 mLs NS per vial and push over ≥ 3 minutes. Infusion: Add 40mg to 100ml Gastric pH monitoring may be needed in select patients. Etomidate X X Per moderate sedation protocol X Moderate sedation service + sedation RN X 2mg/ml 20 and 40mg vials Moderate Sedation for Short Procedures: -.1- 0.2mg/kg/dose RSI/ induction of Anesthesia: 0.3mg/kg IV (-.2- 0.6mg/kg) IVP: Over 30-60 seconds Has no analgesic properties. Requires moderate sedation monitoring with procedure related use. May result in transient myoclonus. Avoid small vessels on the dorsum of the head or hand. May cause discomfort at injection site.
  • 9. Pediatric Guidelines for IV Medication Administration NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist. Version 9/28/2008 Barb Maas Pharm. D. 9 Approved For Drug ICU ED Telemetry Required Acute Care IV P IV Infusion Concen tration Usual Dosing and Administration Comments Famotidine (Pepcid®) X X X Dilute to >=4mg/ml <3 months: 0.5 mg/kg/dose once daily 3 mths-1 yr: 0.5 mg/kg/dose twice daily 1-12 yrs: 0.5-1 mg/kg/day divided twice daily IVP: Over > 2 minutes. MAX 10 mg/min Infusion: Over 15-30 minutes MAX DOSING: 2mg/kg/day Gastric pH monitoring may be needed I select patients Fentanyl(Sublimaze® ) HIGH RISK MED X X Moderate sedation service Only Epidural OK X X 50 mcg/mL IVP 2000 mcg/100 mL MAX: 2000 mcg/40 mL 5000 mcg/ 100 mL Younger infants: Bolus: 1-2 mcg/kg/dose over 3- 5 mins; may repeat every 2-4 hrs. Doses >5 mcg/kg over 5-10 minutes. Infusion: 1-2 mcg/kg bolus, then 0.5-1 mcg/kg/hr; titrate to desired effect Older infants and children 1-12 years: Bolus: 1- 2 mcg/kg/dose over 3-5 mins; may repeat every 30-60 mins. Doses >5 mcg/kg over 5-10 minutes. Infusion: 1-3 mcg/kg/hr; titrate to desired effect. Titrate to patient response using age appropriate pain scale.Peak response 5-10 minutes post dose. Monitor respiratory rate, blood pressure, heart rate, oxygen saturation, and bowel sounds. Rapid IV push may cause apnea/ muscle and chest wall rigidity. Fenoldopam (Corlopam® ) X X X 10 mg/mL vial STD infusion 10mg/250NS (40mcg/ml) MAX Infusion 10 mg/100 mL NS (100 mcg/mL) Usual dosing: 0.1-0.8 mcg/kg/minute Recommended MAX 1.6 mcg/kg/min Titrate: 0.05-0.1 mcg/kg/minute q 10-20 minutes Do not bolus or flush line. Monitor HR, BP, EKG, renal function Filgastim (G-CSF, Neupogen® ) X X S C X Dilute with D5W only to a concentration greater than or =15 mcg/mL (ie//300 mcg/ 20-50 mLs). Infusion over 15-30 minutes. Incompatible with NS. Dosing: 5-10 mcg/kg/day Do not administer 12 hrs before or after radiotherapy. Fluconazole (Diflucan® X X X Dilute to <2 mg/mL Infusion: <6 mg/kg up to 400 mg over 1 hr > 6 mg/kg over 2 hrs Dosing: 3-12 mg/kg/day Flumazenil (Romazicon® ) X X X 0.1 mg/mL 0.01 mg/kg (MAX dose: 0.2 mg) given over 15-30 seconds. May repeat after 45 seconds and then every min to MAX total cumulative dose 0.05 mg/kg or 1 mg, whichever is lower. See dosing table. Monitor level of consciousness and resedation, airway, BP, HR and RR.
  • 10. Pediatric Guidelines for IV Medication Administration NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist. Version 9/28/2008 Barb Maas Pharm. D. 10 Approved For Drug ICU ED Telemetry Required Acute Care IV P IV Infusion Concen tration Usual Dosing and Administration Comments Folic Acid (Folvite® ) X X X X 0.1 mg/mL Infants: 15 mcg/kg/dose daily or 50 mcg daily 1-10 years: 1 mg/day initial; maintenance 0.1-0.4 mg/day >11 years: Initially 1 mg/day; maintenance 0.5 mg/day MAX rate: 5 mg/min Monitor CBC with differential Fosphenytoin (Cerebyx® ) Note:preferred over phenytoin, write all doses as PE equivalents X X X 25 mg PE/mL Loading dose: 10-20 mg PE/kg not to exceed 3mg PE/kg/min up to 150 mg PE/.minute Maintenance: 4-8 mg PE/kg/day in 2-3 divided doses Doses of fosphenytoin are expressed in phenytoin equivalents (PEs). Monitor ECG, BP and RR during loading dose q 5 minutes and for ≥ 30 minutes thereafter. Monitor serum phenytoin levels, CBC, platelets, glucose and LFTs. Furosemide (Lasix® ) X X X X 10 mg/mL 100 mg/100 mL IVP: MAX rate: 0.5 mg/kg/min up to 20 mg/minute IVP; 0.5-2 mg/kg/dose every 6-12 hrs (MAX 6 mg/kg/day) Infusion: 0.05-0.4 mg/kg/hr Monitor I & O, electrolytes, renal function, BP; in high doses monitor hearing. Gentamicin X X X Dilute to 2 mg/mL 40mg/ml for IM use Infusion:Administerover 30 minutes. Peak levels drawn 30 minutes after infusion completed. Trough levels just before dose. Infants > 7 days and children <5yrs: 2.5 mg/kg/dose every 8 hours; once daily dosing: 5-7.5 mg/kg/dose every 24 hrs Children >5 years: 2-2.5 mg/kg/dose every 8 hours; once-daily: 5-7.5 mg/kg/dose every 24 hours. Cystic Fibrosis: 5 mg/kg/dose q 12 hr or based on previous dosing history. For other dosing, please see reference for dosing for specific indications. Monitor serum levels, urine output, and serum creatinine, drug levels.
  • 11. Pediatric Guidelines for IV Medication Administration NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist. Version 9/28/2008 Barb Maas Pharm. D. 11 Approved For Drug ICU ED Telemetry Required Acute Care IVP IV Infusion Concen- tration Usual Dosing and Administration Comments Insulin Regular (NovolinR® ) HIGH RISK MED X X In Code X X < 50kg: 25 units/50 mlsMAX: 100 units/ 100 mL IVP: Over 1 minute Infusion: (regular insulin only) DKA: Initial0.05-0.1 units/kg/hour up to 10 units/hr, titrate to response. > 50 kg: Normoglycemia in ICU..see adult protocol Hyperkalemia: after calcium and bicarb administration, infuse dextrose 0.5-1 gm/kg over 15-30 minutes followed by insulin 0.1units/kg Critical illness hyperglycemia: Review indications with ICU attending. Usual starting dose 0.02-0.05 units/kg/hr titrateto maintain blood glucose 80-140 Monitor urine sugar, blood sugar and electrolytes. Drug may adsorb to IV bag and tubing, when using new tubing, prime, wait 30 mins, then flush tubing prior to starting infusion. Iron Sucrose (Venofer) X X X X May give undiluted, or as an infusion of < 2mg/ml Dosing: Refer to dosing references. Limited pediatric dosing available. IVP: Give each 100mg over 2-5 minutes (MAX 200mg) Infusion: Each 100mg over 15-30 minutes No test dose required. May cause hypotension, esp w/ IVP. .Hypotension may be rate related. Ketamine (Ketalar® ) X X X for moderate sedation, MD present X X Critical care areas only 20mg/ml, 50mg/ml Infusion 200 mg/100 mL NS 500mg/250ml IVP: 0.25-2 mg/kg not to exceed 0.5 mg/kg/min. Supplemental doses usually 1/3 to ½ of initial dose. Infusion: Usual for analgesia/sedation or bronchospasm 5-20 mcg/kg/minute Monitor RR, BP,HR, O2 sats. Avoid in patients with increased ICP or hypertension Increases oral secretions. Pretreatment with glycopyrrolate is recommended if used for monitored sedation. Ketorolac (Toradol® ) X X X 15 mg/mL 30 mg/mL IVP: Over 1-2 minutes Bolus: (optional): > 2yrs. MAX 1 mg/kg up to 60 mg x 1 Maintenance: > 6 months 0.25-0.5 mg/kg/dose (MAX 30 mg given every 6 hours as needed, not to exceed 20 doses/treatment course. Monitor for signs of pain relief, BUN, creatinine, liver enzymes, blood loss and urine output. Stop before surgery due to prolonged bleeding Labetalol (Normodyne® , Trandate® ) X X See comments X MD avail- able X X Critical care areas only 5 mg/mL 500 mg/250 mL 900 mg/250 mL Bolus: 0.25-0.5 mg/kg/dose up to 1mg/kg MAX rate: 0.25mg/kg over 3 minutes up to 10mg/minute. Peak effect 5-15 minutes, duration 2-4 hrs. Infusion: 0.4-3 mg/kg/hour > 50kg: 2-6mg/minute ECG monitoring ,HR, and BP recommended during administration. Monitor heart rate and blood pressure every 5 mins until stabilized and every 15 mins during hypertensive episode up to 30 minutes post dose. Patient should remain supine up to 3 hrs post dose. Monitor blood pressure and heart rate pre/post dosee Infusion allowed in ICU only.
  • 12. Pediatric Guidelines for IV Medication Administration NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist. Version 9/28/2008 Barb Maas Pharm. D. 12 Approved For Drug ICU ED Telemetry Required Acute Care IVP IV Infusion Concen- tration Usual Dosing and Administration Comments Lepirudin (Refludan® ) X X X X IVP Dilute to 5 mg/mL. Infusion: 100 mg/250 mL Requires hematology/oncology approval! May contact anticoagulation service for dosing recommendations and monitoring. Dosing adjustment with renal impairment required. Bolus: 0.4 mg/kg not to exceed 44 mg over 15-20 seconds. Infusion (continuous): Initially 0.15 mg/kg/hr not to exceed 16.5 mg/hr, titrate based on an aPTT. Monitor aPTT, renal function, and for signs and symptoms of bleeding. Levetiracetam Keppra® X X X Dilute to < 15mg/ml w/NS Dosing:20-60mg/kg/day divided q12hrs MAX 4GM/day Infusion:Over 15 minutes Levofloxacin (Levaquin® ) X X X Dilute to 5 mg/mL Infusion: Over 60-90 minutes 6 mths-5 yrs: 10 mg/kg/dose every 12 hours(limited data). Children> 5 yrs: 10 mg/kg/dose every 24 hrs (MAX dose: 500 mg) Adolescents/Adults: 250-750 mg IV q 24 hrs Too rapid infusion may cause hypotension. Monitor renal, hepatic, and hematopoietic function periodically; number and types of stools/day for diarrhea. Levothyroxine (Synthroid® ) X X X X May dilute w/NS to 40 mcg/mL (5 mLs/200 mcg) IVP: Dilute vial with 5 mL NS, use immediately, administer over 2-3 minutes. Discard remainder. See age specific initial dosing, or per endocrine; IV form is 50% of PO recommendation. IV dose usually 50% of oral dose. Monitor T4, TSH, heart rate, clinical signs of hypo- and hyperthyroidism.May be used as a continuous infusion prior to organ donation— Lidocaine X X X Code only X X 20 mg/mL IVP 2 grams/250 mL Load: 1-1.5 mg/kg over 2-4 minutes up to MAX 0.7 mg/kg/min up to 50 mg/minute, MR 0.5-1 mg/kg Q 5-10 minutes X 2 Infusion: 20-50 mcg/kg/min MAX up to 6 mg/min in adults (usual 1-4 mg/min). Monitor EKG, HR, BP.UO, LFT’s and serum concentrations with continuous infusion & IV site for thrombophlebitis if via peripheral administration. Contra- indicated with heart block. Lower dosing may be required with severe CHF or hepatic impairment. Linezolid (Zyvox® ) X X 2 mg/mL Infusion: Over 30-120 minutes < 12yo: 10 mg/kg/dose q 8-12 hrs up to 600 mg/dose >12yo/adult: 400-600 mg q 12 hrs Requires ID approval. Avoid foods/beverages high in tyramine to avoid hypertension (consult nutrition)
  • 13. Pediatric Guidelines for IV Medication Administration NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist. Version 9/28/2008 Barb Maas Pharm. D. 13 Approved For Drug ICU ED Telemetry Required Acute Care IVP IV Infusion Concen- tration Usual Dosing and Administration Comments Lorazepam (Ativan® ) X X X X ICU only IVP: May be diluted to 1 mg/mL w/ NS MAX 4 mg/mL Infusion 50 mg/50 mL 250 mg/250 mL IVP: Not to exceed 0.05 mg/kg over 2-5 minutes up to 2 mg/minute Dosing:0.02-0.1 mg/kg/dose (given every 4-8 hours as needed). Initial MAX 2 mg for sedation, 4 mg for seizures. Infusion:0.05-0.15 mg/kg/hr up to 2 mg/kg/day or 100 mg/DAY whichever is less. (see comments) Usual adult initial dosing 0.5-2mg/hr Monitor respiratory rate, blood pressure, heart rate and symptoms of anxiety. Monitor for phlebitis/ infiltration with peripheral access. With normal renal function, doses approaching 3 mg/kg/day( up to 170 mg/24 hrs should be monitored for propylene glycol toxicity (hyperosmolarity, lactic acidosis, renal toxicity) . Other adult studies have recommended doses not to exceed 1mg/kg/day .Patients with renal compromise should switch to oral lorazepam, seek alternative agents, or monitor for toxicity using lower dosing. Infusion ICU only. Magnesium Sulfate X X X PEDI STD: 1 GM/25 mLS (40 mg/mL) ADULT: 1 gram/50 mL 2 grams/50 mLs Asthma: 25-75 mg/kg over 20 minutes Torsades/PALS: 25-50 mg/kg over 10-20 minutes Repletion(non-acute): 25-50 mg/kg/dose infused over 2-4 hrs Can cause hypotension with too rapid infusion.Monitor serum magnesium, deep tendon reflexes, respiratory rate and blood pressure. 1 gm=8.12 mEq=98.6 mg Magnesium Mannitol (Osmitrol® ) X X X Low dose X 12.5 grams/ 50 mL (25%) 50 grams /250 mLs (20%) IVP: 0.2gm/kg over 3-5 minutes Infusion: 0.25-1 gm/kg over 15 -60 minutes. Requires inline filter. Central line preferred. Monitor for extravasation. Evaluate dose for crystal formation prior to administration. In-line <5 micron filter should always be used with concentrations >20%. . Central line preferred. Extravasation may cause edema and necrosis. Monitor renal function, daily I & Os, serum electrolytes, serum and urine osmolality. Meperidine (Demerol® ) HIGH RISK MED X X X slow X Dilute to < 10 mg/mL IVP slow: 1 mg/kg/dose over 3-5 minutes every 3-4 hours as needed; administer over ≥ 5 mins (do not exceed 25 mg/min) MAX 100 mg/dose, up to 6 mg/kg/day. Avoid repeated doses with renal dysfunction. Restricted use to post-anesthesia shivering and rigors. Monitor respiratory and cardiovascular status and level of sedation, and pain. Meropenem (Merrem® ) X X X X Dilute to 20 mg/mL IVP: Over 3-5 minutes Infusion: Over 15-30 minutes Dosing: 20-40 mg/kg/dose q 8hrs up to 2 Gm/dose Requires ID approval.
  • 14. Pediatric Guidelines for IV Medication Administration NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist. Version 9/28/2008 Barb Maas Pharm. D. 14 Approved For Drug ICU ED Telemetry Required Acute Care IVP IV Infusion Concen- tration Usual Dosing and Administration Comments Methadone (Dolophine® ) HIGH RISK MED X X X 10 mg/mL Dilute w/ NS to volume needed to infuse over 15 minutes Infusion: Over 5-15 minutes Initial Dose in narcotic naïve patients: 0.05-1 mg/kg/dose up to 10 mg/dose q 6-12 hrs(1st 24 hrs) , as drug accumulates over 24-96 hrs, , dosing frequency may need to be reduced to q 12-24 hrs. Monitor RR, HR, BP, sedation and pain levels. Abstinence scoring is used for withdrawal. Monitor for QT prolongation in patients with risk factors. Methyldopa (Aldomet® ) X X Dilute with D5W to < 10 mg/mL Initial: 2-10 mg/kg/dose every 6-8 hours. MAXdose 1 gm, Daily dose: 65 mg/kg or 3 grams, whichever is less. Infusion:Administer slowly over 30-60 mins Onset: 4-6 hrs Duration: 10-16 hrs Monitor blood pressure, CBC with differential, hemoglobin, hematocrit, and liver enzymes. Methylprednisoloneso dium succinate (Solu-Medrol® ) X X X <1.8 mg/ kg X 40 mg, 125 mg, 500 mg & 1 g vial Dosing: 0.5-2 mg/kg/day as high as 30 mg/kg depending on indication. IVP: <1.8 mg/kg up to 125 mg over 3-15 minutes Infusion:May dilute each 1gm dose in a minimum of 100 mls NS (10mg/ml) (exception: spinal cord injury protocol < 2mg/kg: administer over 1-3 minutes >2 mg/kg: administer over 15-30 mins 15 mg/kg up to 500mg: Administer over >+30 minutes >15 mg/kg up to 1 Gm: Administer over 1 hour Caution: Methylprednisoloneacetate is for IM use only. Monitor blood pressure, serum glucose and electrolytes. Metoclopramide (Reglan® ) X X X Low dose X 5 mg/mL Dosing: 0.1-1 mg/kg/dose q 4-6 hrs IVP: Low dose 0.1 mg/kg up to 10 mg over 1-2 minutes Infusion over 15-30 mins (MAX rate: 5 mg/min) Consider pretreatment with diphenhydramine for doses > 0.25 mg/kg. Monitor for EPS. Too rapid administration may cause anxiety Administer diphenydramine for patients Metronidazole (Flagyl® ) X X X 5 mg/mL Dosing: 20-45 mg/kg/day up to 4 gms/day divided every 6 or 8 hrs Infusion: Over 60minutes Do not refrigerate. Doses other than 500 mg will be found in the Pyxis drop-off box. Midazolam (Versed® ) X X Per monitored sedation protocol X for moderate sedation, MD present X X <50kg: 50mg/100ml MAX: 100 mg/100 mL 1 mg/mL, 5 mg/mL 6 months-5 years: Initial 0.05-0.15 mg/kg (MAX total dose: up to 0.6 mg/kg up to 6 mg) 6-12 years: 0.025-0.05 mg/kg (MAX total dose: up to 0.4 mg/kg up to 10 mg in non- intubated patients) IVP: over 2-5 mins, longer for higher doses Infusion: 0.06-0.4 mg/kg/hour MAX 0.4 mg/kg/hr Monitor level of sedation, respiratory rate, blood pressure, heart rate and oxygen saturation
  • 15. Pediatric Guidelines for IV Medication Administration NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist. Version 9/28/2008 Barb Maas Pharm. D. 15 Approved For Drug ICU ED Telemetry Required Acute Care IVP IV Infusion Concen- tration Usual Dosing and Administration Comments Milrinone lactate (Primacor) X X X 1 mg/mL 10 mLs Infusion: 20 mg/100 mL Load: 25-100mcg/kg over 15 mins Infusion: 0.2-1.2 mcg/kg/min Monitor EKG, BP, HR, UO platelet count, potassium, renal function, signs and symptoms of HF Morphine Sulfate HIGH RISK MED X X X slow X 2, 4, 10 mg/ml PCA 1, 5 mg/mL INF: 1mg/ml 100 or 250ml MAX: 500 mg/ 100 mL Bolus: 0.05-0.1 mg/kg/dose up to initial MAX 10 mg over 5-30 mins Infusion: Initial 0.005-0.15 mg/kg/hr; titrate to patient pain response and tolerance. Monitor HR, RR, BP, oxygen saturation, pain relief and level of sedation. Nafcillin (Nafcil® ) X X X slow X 20 mg/mL 1-1.5 gm/ 50 mLs 1.6-2 gm/100 mLs Dosing: 50-200 mg/kg/day divided q 4 or q 6 hrs MAX 12 gms/day IVP: Over 5-10 minutes Infusion: Over 30-60 minutes Monitor for burning, extravasation, phlebitis Nalbuphine (Nubain® ) X X X slow X 10 mg/mL 20 mg/mL Premed: 0.1-0.2 mg/kg MAX 20gm Analgesia: 0.05-0.15 mg/kg every 3-6 hours as needed. Initial MAX 10 mg MAX: 20 mg/dose up to 160 mg/day IVP: Administer over 3-5 mins Infusion:Over 15 mins Monitor relief of pain, respiratory and mental status, and blood pressure.
  • 16. Pediatric Guidelines for IV Medication Administration NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist. Version 9/28/2008 Barb Maas Pharm. D. 16 Approved For Drug ICU ED Telemetry Required Acute Care IVP IV Infusion Concent ration Usual Dosing and Administration Comments Naloxone (Narcan® ) X X X X 0.4 mg/ mL IVP dilution: < 40 kg 0.1 mg in 9.75 mLs NS =(0.01mg/mL) > 40 kg 0.4 mg in 9 mLs NS= (0.04mg/mL) Infusion: 4 mg/100 mLs NS (0.04 mg =40 mcg/ mL) Post anesthesia narcotic reversal: Narcotic naïve: 0.005-0.01 mg/kgIVP q 2-3 mins as needed Opiate dependent: 0.001-0.002 mg/kg IVP q 2-3 mins as needed(1/10th -1/5th usual dose to prevent acute withdrawal) IVP: Over 30 seconds Narcotic-induced pruritis: 0.25-2 mcg/kg/hr; increase by0.25- 0.5 mcg/kg/hr every few hours as needed Opiate intoxication: (narcotic naïve) <20 kg: 0.1 mg/kg every 2-3 minsprn >20 kg: 2 mg/dose every 2-3 minsprn Opiate dependent: (1/10th -1/5th usual dose to prevent acute withdrawal) Infusion: calculate initial dose/hour based on effective intermittent dose used and titrate; range: 2.5-160 mcg/kg/hour Monitor respiratory rate, heart rate, and blood pressure. The duration of action of naloxone is shorter than most opiates (20-30 minutes). Patients who receive naloxone should be monitored for reoccurance of respiratory depression. Patients with acute pain will require careful titration to maintain analgesia while reversing respiratory depression. Neostigmine (Prostigmin®) X X X slow 0.5 mg/ml 1 mg/mL Non-depolarizing NMB reversal: with atropine or glycopyrrolate Infants: 0.025-0.1 mg/kg/dose Children: 0.025-0.08 mg/kg/doseMAX/DOSE (see adult) Myasthenia gravis treatment: 0.01-0.04 mg/kg every 2-4 hoursMAX/DOSE (see adult) Adult: 0.5-2.5 mg, MAX 5 mg IVP: Administer over several minutes up to 0.5mg/min Atropine or glycopyrrolate recommended prior to neostigmine. Epinephrine should be available. Monitor HR, BP,RR, muscle strength. Nicardipine (Cardene) X X X Standard/Periph eral- Add 25 mg to 250 mLs NS (0.1mg/mL) MAX/Central: Add 100 mg to 60 mLs NS (1 mg/mL) Infusion: IF< 50 kg Initial 0.5-5 mcg/kg/minute If >50 kg: 2.5-15 mg MAX: 15 mg/HOUR. Titrate q 5-30 minutes Monitor blood pressure and heart rate Nitroglycerin X X X 100 mg/250 mLs Infusion: If < 50 kg 0.25-1 mcg/kg/min titrate by 0.5-1 mcg/kg/min every 3-5 mins as needed. MAX 20 mcg/kg/min >50 kg:5 mcg/min, titrate by 5-10 mcg/minq 3-5 mins up to 300 mcg/min Monitor blood pressure and heart rate. Protect the drugfrom light.
  • 17. Pediatric Guidelines for IV Medication Administration NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist. Version 9/28/2008 Barb Maas Pharm. D. 17 Approved For Drug ICU ED Telemetry Required Acute Care IVP IV Infusio n Concentrati on Usual Dosing and Administration Comments Nitroprusside (Nipride) X X X 100 mg/ 250 mL Infusion: 0.3-5 mcg/kg/min Titrate by 0.1 mcg/kg/min q 2-3 minutes MAX 10 mcg/kg/min Protect the drugfrom light. Do not use if blue-green in color. Monitor blood pressure, heart rate, cyanide and thiocyanate toxicity; monitor acid-base status as acidosis can be early sign of cyanide toxicity; monitor thiocyanate levels if infusion needed for >3 days or dose >4 mcg/kg/min or in renal dysfunction; monitor cyanide levels in hepatic dysfunction. Norepinephrine (Levophed) X X X <10 kg 8 mg/250 mL 10-50 kg + MAX 16 mg/250 mL >50 kg4 mg/250 mL Infusion:Initial 0.05-0.1 mcg/kg/min. Titrate by 0.1-0.2 mcg/kg/minute every 5 minutes till desired effect or toxicity Recommended MAX 2 mcg/kg/min Monitor blood pressure, heat rate, urine output, and peripheral perfusion. Central line preferred. Octreotide Acetate (Somatostatin) Note: not to be confused with Sandostatin LAR Depot IM injection X X X X 50, 100, 500 mcg vial for SC/IV admin Standard infusion: 500 mcg in 100 mLs NS/D5W (5 mcg/mL) REFRIGERAT ED Hypoglycemia/Antisecretory: 2-10 mcg/kg/day divided q 8 or 12 hours or as continuous infusion: titrate to patient response by increasing dose or interval; GI bleed/esophageal varices:0.5-1 mcg/kg bolus, then 1 mcg/kg/hour continuous infusion; titrate to response(usual adult 25-50 mCG/HR) MAX DOSE: 1500 mcg/day SC: usual bolus route IV: infuse over 15-30 mins in NS IVP: over 3 minutes Monitor baseline and periodic ultrasound evaluations for cholelithiasis, blood sugar, thyroid function tests, fluid and electrolyte balance. Ondansetron (Zofran) X X X X 2 mg/mL Chemo induced N/V: Children: 0.15 mg/kg/dose MAX 0.45 mg/kg/day up to 32 mg Nausea/Vomiting: Children >2 yrs <40 kg: 0.1 mg/kg Children >40 kg: 4 mg IVP: undiluted over 1-5 minutes Infusion: over 15 minutes in NS/ D5W Monitor blood pressure and heart rate. May cause headache.
  • 18. Pediatric Guidelines for IV Medication Administration NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist. Version 9/28/2008 Barb Maas Pharm. D. 18 Approved For Drug ICU ED Telemetry Required Acute Care IVP IV Infusion Concentr ation Usual Dosing and Administration Comments Pamidronate (Aredia) X X X Prepared by pharmacy. Volume varies by dose. Hypercalcemia/osteopenia:0.5-1 mg/kg (MAX dose of 90 mg). Do not redose within 7 days. Infusion: Over 2-24 hrs. (Longer infusion times ↓ the risk of nephrotoxicity.) Infuse in dedicated line. Thrombophlebitis. Monitor serum creatinine prior to each dose, urine output, serum electrolytes, phosphate, magnesium, hemoglobin, hematocrit, CBC with differential. Pentobarbital (Nembutal) X X Continuous Infusion Or per moderate sedation protocol X for moderate sedation, MD present X slow X 50 mg/mL Infusion: 2500 mg/ 50 mls (50 mg/ml) Sedation: Children >6–18 mths: 1-3 mg/kg Children >18 mths: 2 mg/kg, then 1-2 mg/kg every 5-10 minsuntil adequate sedation MAX: 100 mg/dose *IVP: slowly (<1 mg/kg/min up to 50 mg/min) Used only with conscious sedation monitoring or in ICU/ER. IV: Over 10-30 minutes. May be further diluted to no less than 5 mg/mL with NS. Do not use unless solution is clear. Pentobarbital Coma: Load: 15-35 mg/kg over 1-2 hrs Infusion: 1-5 mg/kg/hr viadedicated central line preferred. MAX: 10 mg/kg/hr Monitor vital signs, blood pressure, respiratory status, cardiovascular states, CNS status. Monitor for thrombophlebitis/extravasation. Central linr preferred and particulate filter required with continuous infusions. Check infusion regularly to monitor for precipitation. For pentobarbital coma, also monitor EEG bursts.. Phenobarbital (Luminal) X X X 65 mg/mL 130mg/ml Anticonvulsant: Load: 15-18 mg/kg at 1-2 mg/kg/minute (MAX 60 mg/minute). Maintenance: IV: < 1 mg/kg/min up to 30 mg/minute Infants: ≤ 5 mg/kg/day in 1-2 doses 1-5 yrs: 6-8 mg/kg/day in 1-2 doses 5-12 yrs: 4-6 mg/kg/day in 1-2 doses >12 yrs: 1-3 mg/kg/day in 1-2 doses Monitor CNS status, seizure activity, LFTs, CBC, renal function, serum concentrations, respiratory rate, heart rate, blood pressure, Phenylephrine (Neo-synephrine) X X X ICU/ ER only X (for<10 kg) 5 mg/250 mL (10-+kg) 10 mg/250 mL MAX CONCENTR ATION 60 mg/250 mL Hypotension/Shock: Usual 0.1-0.5 mcg/kg/min; titrate to desired effect PSVT: 5-10 mcg/kg over 20-30 seconds (Adult: 0.25-0.5 mg) Monitor heart rate, BP/MAP, CVP. Central line preferred
  • 19. Pediatric Guidelines for IV Medication Administration NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist. Version 9/28/2008 Barb Maas Pharm. D. 19 Approved For Drug ICU ED Telemetry Required Acute Care IVP IV Infusion Concent ration Usual Dosing and Administration Comments Phenytoin sodium (Dilantin® ) Note:Fosphenytoin should be used in children instead phenytoin X X X 50 mg/mL (mustdil- ute to 1-5 mg/mL in NS) Acute Seizures Load: 15-20 mg/kg in a single or divided doses MAXinfusion rate: Neonates: 0.5 mg/kg/min Children: 1-3 mg/kg/min not to exceed 50 mg/min Maintenance: 4-8 mg/kg/day in 2-3 divided doses Loading doses: Monitor HR/ BP and RR during loading dose q 5 minutes and for ≥ 30 minutes thereafter. Telemetry monitoring recommended if patient has significant underlying cardiac disease. Particulate filter required. Check for extravasation. Monitor serum levels, CBC, LFTs, and blood pressure. Phosphate as Sodium Phosphate Each 1 Meq Na+ = 0.75mM Phos, 1mMPhos = 1.33Meq Na+ Potassium Phosphate Each mMPhos= 1..47 meq K+ 1 meq K+ = 0.68mM Phos X X X All IV doses prepared by pharmacy. Volume depends on dose and whether via central or peripheral adminis tration. Dosing in MMols: Hypophosphatemia: Phos> 2: 0.05-0.1 Mm/kg up to 15mM Phos 1-2 mM/dl- 0.16-0.25mM/kg up to 30Mm Phos< 1mM/dl: 0.25-0.4mM/kg up to 0.6mM/kg to MAX 30mM/dose or 45mM/day IV infusion: Doses < 0.5mM/kg or 30mM over 4 hrs. Doses >=0.5mM/kg or 30Mm over 6 hrs Maximum Concentration: Peripheral 30mM Phos/L (1.5mM per 50mls Central: 30mM Phos/250 mls= 6mM per 50 mls INFUSION: Intermittent doses over 4-6 hrs. MAX: 0.06mM/kg/hr **in pediatrics, order doses in 50, 100, 150, 250, 500, OR 1000 ml volumes. **caution: for Kphos orders written in mM be aware of K+ dose pt will also be recieving Phytonadione (Vitamin K, Mephyton® ) X SC/IM only X (ICU/ OR/ER only) 10 mg/mL 1 mg/mL *SC, IM, or PO preferred. Dose: 1-10 mg, Usual 1-2.5 mg IV(restricted) : Dilute w/ NS to volume needed to administer over 15-30 minutes. (see comments) Monitor for potential hypersensitivity reactions, flushing. Monitor BP, HR, RR.@ baseline then q 5 min during infusion . Piperacillin/Tazobactm (Zosyn® ) X X X 60 mg piperacillin and7.5 mg tazobactam/ mL 2.25 g/50 ml 3.375 g/50 mL 4.5 g/50 mL Infants <6 mths: 150-300 mg of piperacillin component/kg/day in divided doses every 6-8 hours >6 mths: 200-350 mg of piperacillin component/kg/day in divided doses every 6-8 hours. CF: 350-450 mg/kg/day divided q4h or q6 hrs MAX 4.5gm/dose IV:Over ≥ 30 minutes Monitor serum electrolytes, bleeding time especially high dose or w/ renal impairment. periodic tests of renal, hepatic, and hematologic function. Potassium Chloride HIGH RISK MED X X For IV doses exceeding 0.3meq/kg/hr up to 10meq/hr X X Pedi: 0.4 mEq/mL-25 mL vials for central bolus doses (10 mEq) 20 mEq/50 ml bags Maintenance: Usual daily dose 2-5mEq/kg/day (Adult usual: 40-80 mEq/day.) Hypokalemia: Dosing depends on severity, etiology, and renal function. See comments on individual dosing limitations. MAX: Peripheral 0.06 mEq/mL (60 mEq/L) Central 0.4mEq/mL RATE: non-telemetry <0.3 mEq/kg/hr up to 10 mEq/hr Telemetry-0.6 mEq/kg/hr up to 20 mEq/hr Monitor serum potassium, glucose, chloride, pH, urine output if indicated
  • 20. Pediatric Guidelines for IV Medication Administration NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist. Version 9/28/2008 Barb Maas Pharm. D. 20 Approved For Drug ICU ED Telemetry Required Acute Care IVP IV Infusion Concen tration Usual Dosing and Administration Comments Prochlorperazine (Compazine® ) X X X X 5 mg/mL Antiemetic: Children >10 kg: Dose IV/IM: 0.1-0.15 mg/kg/dose every 6-12 hours (MAX: 10mg/dose) IV: May be further diluted in a sufficient volume with NS and administered over 15-30 minutes IVP: Administer at MAX rate of 0.1 mg/kg/minute(MAX 5 mg/min) In children < 5yo, reserve this agent for patients who are unresponsive to other alternatives due to the higher risk of extrapyramidal effects. Alternative routes to IV preferred. Monitor for extrapyramidal reactions, hypotension, and signs of extravasation. Promethazine (Phenergan® ) X X X 25 mg/mL Not recommended in patients < 2yrs of age due to significant respiratory depression. For use in children >2 years. Oral/rectal routes preferred. Antiemetic: 0.25-1 mg/kg (MAX dose: 25 mg in children, 50 mg in adolescents) 4-6 times/day as needed. Begin with lowest dose. Usual Adult Dose: 12.5-25 mg IV: Further diluted 1:10 (v/v) or greater in NS to minimize extravasation injuryand administered over 10- 20 minutes. Monitor for extrapyramidal reactions, respiratory depression, hypotension, and signs of pain and extravasation. Propofol (Diprivan® ) X X X Moderate sedation service + moderate sedation RN X X 10 mg/mL 200 mg/20 mLs 500 mg/50 mLs 1000 mg/100 mLs Do not dilute to less than 2 mg/mL with D5W (even via y-site) due to emulsion instability. ICU SEDATION: (> 24 hrs) Infusion 5-50 mcg/kg/minute. Titrate upward by 5-10 mcg/kg/min q 5-10 minutes to desired level of sedation and as hemodynamically tolerated. PRN boluses w/ infusion: 0.25-1 mg/kg up to 50 mg/dose MAX MAINTENANCE ICU sedation rate not to exceed 50 mcg/kg/minute. MONITORED PROCEDURAL SEDATION- Initiation: IVP: 0.5-3 mg/kg over 20-30 seconds OR 0.25-0.5 mg/kg/dose MAX 40 mg/dose q 10 seconds OR 100-300 mcg/kg/min x 3-5 minutes, then titrate to desired effect Maintenance infusion: usual 50-300 mcg/kg/min Avoid in patients with significant peanut/ soy/ or egg allergies. Monitor respiratory rate, blood pressure, heart rate, oxygen saturation, ABGs, depth of sedation, serum lipids or triglycerides if use is >24 hours. To minimize pain at injection site, administer through central line or large peripheral veins. Use filter with pore size > 5 microns. Insure strict aseptic technique. Unused drug and tubing must be discarded every 12 hrs to minimize risk of infection. Drug transferred to syringes must be discarded within 6 hrs. In patients receiving parenteral nutrition, consider amount of fat provided by propofolemulsion in nutrition goal.
  • 21. Pediatric Guidelines for IV Medication Administration NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist. Version 9/28/2008 Barb Maas Pharm. D. 21 Approved For Drug ICU ED Telemetry Required Acute Care IVP IV Infusion Concen tration Usual Dosing and Administration Comments Propranolol (Inderal® ) X X X 1 mg/mL May dilute each MG in 10-50 mLs NS 0.01-0.025 mg/kg slow IV over 10 mins (MAX dose: 0.5 mg/dose for infants and 1 mg/dose for children) Usual adult dose: 1-3 mg slow over 10 minutes, not to exceed 1 mg/minute Conversion from PO to IV unpredictable due to first pass metabolism. Recommend alternative IV hypertensive’s (labetolol or metoprolol for BP control) Monitor blood pressure, CVP, and EKG Protamine Sulfate X X X X 10 mg/mL* * After vial reconstitutio n with 5 mLSWI. May be further diluted with NS or D5W. Dose determined by the most recent time and dosage of heparin or low molecular weight heparin, (please see dosing references) MAX dose: 50 mg MAX rate: IVP < 5 mg/minute Use cautiously in pts with fish or protamine allergies. Hypotension, bradycardia and flushing may be infusion rate related reactions. Continue to monitor coagulation, blood pressure, and cardiac status. Rasburicase (Elitek® ) X X X 1.5 mg/mL Requires oncology attending approval. Prepared by chemo pharmacy in 10-50 mLs NS. 0.15-0.2 mg/kg/dose MAX: 0.4 mg/kg/day for up to 5-7 days. Infuse over 30 minutes. Flush with NS pre- and post infusion. Monitor for potential anaphylaxis. Dedicated line preferred. Do not shake or filter. Recommended as a single course of therapy. Rho(D) Immune Globulin (WinRho® ) X X X Approx 230- 240 units/mL, as 0.5, 1.3, 2.2, 4.4, 13 mL vials Does not require further dilution. Dose for ITP: 25-75mcg/kg slow IV over 3-5 minutes Hgb should be >8 gm/dl prior to administration. May be further diluted with NS. Rocuronium HIGH RISK MED X X 1 mg/mL Infants: 0.5 mg/kg/dose, repeat every 20-30 minutes as needed Children: Initial: 0.6 mg/kg/dose with repeat doses of 0.075-0.125 mg/kg every 20-30 mins to desired effect Infusion: 10-12 mcg/kg/min Monitor peripheral nerve stimulator measuring twitch response, heart rate, blood pressure and assisted ventilator status.
  • 22. Pediatric Guidelines for IV Medication Administration NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist. Version 9/28/2008 Barb Maas Pharm. D. 22 Approved For Drug ICU ED Telemetry Required Acute Care IVP IV Infusion Concen tration Usual Dosing and Administration Comments Sodium Bicarbonate X X X X 5 mEq/10 mL(4.2%) (=0.5 mEq/mL)* *Preferred in infants and small children 50 mEq/50 mL(8.4%) (=1 mEq/mL) Please see reference for dosing for specific indications. Code: 1 mEq/kgdose over 3-5 minutes Non-Code:Not to exceed 1 mEq/kg/hr up to 50 meq/hr Prevention of tumor lysis: 120-200 mEq/m2 /day Monitor serum electrolytes, urinary pH and arterial blood gases if indicated, pain and phlebitis with peripheral administration. Hyperosmolar: Central line preferred, or dilute 1 mEq to 2 or 3 mLs for peripheral administration Verify compatability before Y-site administration with other drugs. Sodium Chloride 3% (hypertonic) 0.513meq Na+/ml X X Symptomatic IsovolemicHyponatremia: uptp4mls/kg/dose over 15 minutes. (equivalent to ~ 12- 15mls/kg NS). HypovolemicHyponatremia:Use NS fluid bolus ICP Management: 1-4 mls/kg undiluted over 15 minutes Central line preferred. For correction of acute hyponatremia, avoid rapid increases in serum sodium. In symptomatic patients or is serum sodium < 120meq/L, target for an initial increase of 4-6meq/L, not to correct beyond 12- 15meq/L per 24hrs Sodium Chloride 23.4%(hypertonic) 4 meq Na+/ml X X Concentrated electrolyte May not be stored at bedside or in pyxis. Available for STAT Call pharmacy. ICP Management Adults: 15-30mls undiluted over 15 minutes Central line required. Monitor serum Na+ and osmolar gap. Succinylcholine HIGH RISK MED X Preferred Emergency intubation only X 20 mg/mL Does not require futher dilution. REFRIGER ATE Initial: 1-2 mg/kg (MAXtotal dose: 150 mg) Administer over 30 seconds. Maintenance: Avoid repeated dosing. 0.3-0.6 mg/kg every 5-10 mins as needed. For short-term administration due to risk of hyperkalemia. Avoid in any patients with neuromuscular disorder/acute burns secondary to risk of hyperkalemia. Avoid with increased ICP. Because of the risk of malignant hyperthermia, use of continuous infusions is not recommended. Monitor heart rate and rhythm, serum potassium, assisted ventilator status, muscle twitching. Sulfamethoxazole and Trimethoprim (Bactrim, Septra® ) X X X 16 mg/mL TMP 80 mg/mL SMZ Note:dosin g based on TMP component Evaluate risk-benefit in infants<2 months:. Avoid use if infant has hyperbilirubinemia or in patients with renal failure. Mild-Mod infections: 6-12 mg TMP/kg/day divided every 12 hours Serious infections: 15-20 mg TMP/kg/day divided every 6-8 hours. Administer MAX concentration of 1:10 dilution (each 5 mL of drug added to no less than 50 mLsof D5W) over 60-90 minutes. Complete infusion within 2 hrs of dilution due to limited stability. Use a particulate filter. Monitor for precipitates, especially in maximally concentrated dilutions. Monitor for rash, phlebitis, urine output, CBC, renal function tests.
  • 23. Pediatric Guidelines for IV Medication Administration NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist. Version 9/28/2008 Barb Maas Pharm. D. 23 Approved For Drug ICU ED Telemetry Required Acute Care IVP IV Infusion Concent- ration Usual Dosing and Administration Comments Terbutaline (Brethine® ) X X X X 1 mg/mLvials Infusion: 20 mg/100 mLs NS (200 mcg/mL) Prepared by pharmacy unless emergent. See infusion chart Bolus: 2-10 mcg/kg (administer from infusion bag0.01- 0.05 mls/kg over 5-10 mins bag) Infusion:0.1-6mcg/kg/minute (MAX 10 mcg/kg/minute).Titrate by increments of 0.1-0.2 mcg/kg/min every 30 mins to desired effect. Monitor heart rate, blood pressure, respiratory rate, serum potassium, CPK, EKG, and blood gases if applicable. Tobramycin (Nebcin® ) X X X Dilute to < 5 mg/mL Infusion:Administerover 30 minutes. Peak levels drawn 30 minutes after infusion completed. Trough levels just before dose. Infants > 7 days and children <5yrs: 2.5 mg/kg/dose every 8 hours; once daily dosing: 5-7.5 mg/kg/dose every 24 hrs Children >5 years: 2-2.5 mg/kg/dose every 8 hours; once-daily: 5-7.5 mg/kg/dose every 24 hours. Cystic Fibrosis: 5 mg/kg/dose q 12 hr or based on previous dosing history. For other dosing, please see reference for dosing for specific indications. Monitor serum levels, urine output, and serum creatinine Tromethamine (THAM® ) X X X 18 gm/500 mLs (0.3 mM/mL) 1 mEq=1 mm= 120 mg per 3.3 mLs Neonates: 1 mL/kg for each pH unit below 7.4. Infants/Children/Adults: Dose (in mLs)= kg X base deficit (mEq/L) X 1.1 up to 13.9 mLs/kg/dose Infusion:Over≥ 1 hr. 0.7-1 mL/kg/hr MAX 23 mls/kg/day. Acute Acidosis: 25% of dose over 5-10 minutes followed by remainder over 1 hr. Intended for short-term use. Central line or large peripheral vein (pH10.5) preferred. Monitor for extravasation, tissue injury, thrombosis. Monitor for respiratory depression, hypoglycemia, hyperkalemia, renal functiom, serum pH, ABG’s, hyperosmolarity Vancomycin (Vancocin® , Vancoled® ) X X X Dilute to <5 mg/mL Central: < 10mg/ml per request if fluid restricted Infusion:Over 60-90 minutes, slower if pt experiencing red-man syndrome (histamine-like reaction). < 7 days: 10-15 mg/kg every 12 hours > 7 days: 10-15 mg/kg every 6-8 hrs Infants> 1 month, children: 40-60 mg/kg/day divided every 6-8 hours up to initial MAX 1.5 gm/dose up to 4 gm/day. Adjust for renal dysfunction. Monitor periodic renal function tests, urinalysis, serum vancomycintrough levels, and WBC. Use caution with concurrent NSAID use and/or dehydration + high dose vancomycin secondary to risk of induced acute renal failure
  • 24. Pediatric Guidelines for IV Medication Administration NOTE: This is not a comprehensive medication list. For items not listed, review standard medication resources or consult the pharmacist. Version 9/28/2008 Barb Maas Pharm. D. 24 Approved For Drug ICU ED Telemetry Required Acute Care IVP IV Infusion Concen tration Usual Dosing and Administration Comments Vasopressin X X X PTS <50 kg: DI: 5 units/ 500 mlsNS SHOCK: 50 units/ 250 mLs NS PTS>50 kg/adults DI: 10 units/250 mls NS SH0CK: 40units/ 100 mLNS IVP: ACLS 40 units over 15-30 seconds PTS <50 kg: DI :0.0005 unit/kg/hr; double dose as needed every 30 mins to MAX 0.01 units/kg/hr SHOCK:0.02-0.12 units/kg/hr up to 2.4 units total/hr PTS>50 kg/adults: DI :0.0005 unit/kg/hr; double dose as needed every 30 mins to MAX 0.01 units/kg/hr Hypotension/Shock: 0.04-0.1 units/MINUTE Central Vein Preferred. Monitor fluid intake and output, urine specific gravity, urine and serum osmolality, serum and urine sodium. Monitor BP, S/S ischemia( digital, gut, coronary) Vecuronium (Norcuron® ) HIGH RISK MED X X X IVP: Dilute to 1 mg/mL Continuous Infusion: 50 mg/100 mL D5W IVP: Over seconds Pedi Dosing: Neonates: 0.05-0.2mg/kg/dose IV q1=2 hrs or per hr as continuous infusion. Monitor assisted ventilator status, heart rate, blood pressure, peripheral nerve stimulator measuring twitch response. Patients must be intubated and properly sedated. Verapamil (Isoptin® , Calan® ) X X X X IVP: 1-2.5 mg/mL Infusion: 50 mg/100 mL D5W IVP: Over 2-5 minutes Children 1-16 years: 0.1-0.3 mg/kg/doseMAX initial dose 5 mg, MR in 15-30 minutes x 1 with MAX of 0.3 mg/kg to 10 mg/dose Not recommended in infants. Monitor EKG, blood pressure and heart rate. IV calcium should be readily available. Voriconazole (VFend® ) X X X Diluted by pharmacy to 0.5-5 mg/mL Infusion: Over 1-2 hrs not to exceed 3 mg/kg/hr Dose:3-6 mg/kg/dose q 12 hr, esophageal candidiasis doses may be lower Patients may commonly experience reversible visual changes. Monitor electrolytes. Use cautiously in patients with proarrythmic conditions. Infectious disease approval required. Do not use IV form in renal failure References Lexi-Comp’s Pediatric Dosage Handbook- 14th Edition Pediatric Injectable Drugs-8th Edition 2008 Intravenous Medications-24th Edition Micromedex UMMMC Adult Guidelines for IV Medication Administration 2007 VUMC IV Medication Administration Chart revised 09/21/04 University of Kentucky Chandler Medical Center Pediatric IVP/Infusion Drug Lists 2005 Children’s Hospital and Clinics of Minnesotta Pediatric IV Administration Guidelines Revised 09/05 Editor: Barbara Maas Pharm. D. Primary Reviewers/Co-editors: Angela Gilchrist Pharm. D., Amy Hellinger Pharm. D., CharlesTurck Pharm. D. Primary Nursing Reviewers: Carol Kronopolis, Charles Wheeler, Lynn D’Angelo, Rosemary Cerquiera Primary Physician Reviewers: Hospitalist- Tom Guggina ICU Attending- Scott Bateman ER Attending-Mariann Manno Appoved by Pharmacy and Therapeutics 09/14/08 Add for future: Cosyntropin, alteplase, lopressor, gancyclovir, immune globulin, sodium chloride 3%, etomidate